CA2144651A1 - Immortalized cells and uses therefor - Google Patents
Immortalized cells and uses thereforInfo
- Publication number
- CA2144651A1 CA2144651A1 CA002144651A CA2144651A CA2144651A1 CA 2144651 A1 CA2144651 A1 CA 2144651A1 CA 002144651 A CA002144651 A CA 002144651A CA 2144651 A CA2144651 A CA 2144651A CA 2144651 A1 CA2144651 A1 CA 2144651A1
- Authority
- CA
- Canada
- Prior art keywords
- immortalized
- cell
- tick
- antigen
- pathogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000004027 cell Anatomy 0.000 claims abstract description 269
- 229960005486 vaccine Drugs 0.000 claims abstract description 69
- 239000000203 mixture Substances 0.000 claims abstract description 43
- 241000283690 Bos taurus Species 0.000 claims abstract description 32
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 19
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 7
- 239000000427 antigen Substances 0.000 claims description 88
- 108091007433 antigens Proteins 0.000 claims description 88
- 102000036639 antigens Human genes 0.000 claims description 88
- 244000052769 pathogen Species 0.000 claims description 84
- 230000001717 pathogenic effect Effects 0.000 claims description 80
- 108090000623 proteins and genes Proteins 0.000 claims description 48
- 241001465754 Metazoa Species 0.000 claims description 36
- 102000004169 proteins and genes Human genes 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 30
- 208000016604 Lyme disease Diseases 0.000 claims description 20
- 230000002163 immunogen Effects 0.000 claims description 20
- 230000001413 cellular effect Effects 0.000 claims description 16
- 208000015181 infectious disease Diseases 0.000 claims description 13
- 241000238682 Amblyomma americanum Species 0.000 claims description 12
- 241000589969 Borreliella burgdorferi Species 0.000 claims description 11
- 230000001105 regulatory effect Effects 0.000 claims description 11
- 238000012258 culturing Methods 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 9
- 201000001064 tick infestation Diseases 0.000 claims description 8
- 229920002521 macromolecule Polymers 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 241000605314 Ehrlichia Species 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 241000606665 Anaplasma marginale Species 0.000 claims description 3
- 206010061217 Infestation Diseases 0.000 claims description 3
- 210000001124 body fluid Anatomy 0.000 claims description 3
- 239000010839 body fluid Substances 0.000 claims description 3
- 230000003053 immunization Effects 0.000 claims description 3
- 241000223838 Babesia bovis Species 0.000 claims description 2
- 241000223779 Theileria parva Species 0.000 claims description 2
- 241000606675 Ehrlichia ruminantium Species 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 49
- 241000589970 Spirochaetales Species 0.000 description 29
- 239000000463 material Substances 0.000 description 19
- 241000589968 Borrelia Species 0.000 description 17
- 241001480819 Dermacentor andersoni Species 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- 241000238876 Acari Species 0.000 description 13
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- 230000000890 antigenic effect Effects 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 210000003743 erythrocyte Anatomy 0.000 description 11
- 238000004113 cell culture Methods 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 235000013601 eggs Nutrition 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 238000003556 assay Methods 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 241000238679 Amblyomma Species 0.000 description 6
- 241000700198 Cavia Species 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 210000003714 granulocyte Anatomy 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 230000005875 antibody response Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 244000045947 parasite Species 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 238000012809 post-inoculation Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000282465 Canis Species 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- 241000605312 Ehrlichia canis Species 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 241001180982 Lappula squarrosa Species 0.000 description 3
- 206010057249 Phagocytosis Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 229940051998 ehrlichia canis Drugs 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- -1 ntigenic Species 0.000 description 3
- 230000008782 phagocytosis Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 241000700570 unidentified entomopoxvirus Species 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241000710961 Semliki Forest virus Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 201000008680 babesiosis Diseases 0.000 description 2
- LFZDEAVRTJKYAF-UHFFFAOYSA-L barium(2+) 2-[(2-hydroxynaphthalen-1-yl)diazenyl]naphthalene-1-sulfonate Chemical compound [Ba+2].C1=CC=CC2=C(S([O-])(=O)=O)C(N=NC3=C4C=CC=CC4=CC=C3O)=CC=C21.C1=CC=CC2=C(S([O-])(=O)=O)C(N=NC3=C4C=CC=CC4=CC=C3O)=CC=C21 LFZDEAVRTJKYAF-UHFFFAOYSA-L 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 229940030156 cell vaccine Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 231100000676 disease causative agent Toxicity 0.000 description 2
- 208000000292 ehrlichiosis Diseases 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- GWUSZQUVEVMBPI-UHFFFAOYSA-N nimetazepam Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1 GWUSZQUVEVMBPI-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 229940124856 vaccine component Drugs 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 125000002030 1,2-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([*:2])C([H])=C1[H] 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000223836 Babesia Species 0.000 description 1
- 239000005996 Blood meal Substances 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 241001034584 Borrelia burgdorferi 297 Species 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 241000736839 Chara Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241001480824 Dermacentor Species 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010039207 Rocky Mountain Spotted Fever Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 101710169783 Spheroidin Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 208000001117 Theileriasis Diseases 0.000 description 1
- 208000035056 Tick-Borne disease Diseases 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000006730 anaplasmosis Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- WXNRAKRZUCLRBP-UHFFFAOYSA-N avridine Chemical compound CCCCCCCCCCCCCCCCCCN(CCCN(CCO)CCO)CCCCCCCCCCCCCCCCCC WXNRAKRZUCLRBP-UHFFFAOYSA-N 0.000 description 1
- 229950010555 avridine Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000023715 cellular developmental process Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- HDRXZJPWHTXQRI-BHDTVMLSSA-N diltiazem hydrochloride Chemical compound [Cl-].C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CC[NH+](C)C)C2=CC=CC=C2S1 HDRXZJPWHTXQRI-BHDTVMLSSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000011554 guinea pig model Methods 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000012007 large scale cell culture Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940042470 lyme disease vaccine Drugs 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000017448 oviposition Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical class O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- QCZWKLBJYRVKPW-LYWCOASQSA-N spheroidene Natural products COC(C)(C)CC=CC(=CC=CC(=CC=CC(=CC=CC=CC(C)C=C/C=C(C)/CCC=C(/C)CC=C(C)C)C)C)C QCZWKLBJYRVKPW-LYWCOASQSA-N 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- RYCLIXPGLDDLTM-UHFFFAOYSA-J tetrapotassium;phosphonato phosphate Chemical compound [K+].[K+].[K+].[K+].[O-]P([O-])(=O)OP([O-])([O-])=O RYCLIXPGLDDLTM-UHFFFAOYSA-J 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 208000016523 tick-borne infectious disease Diseases 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0233—Rickettsiales, e.g. Anaplasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Insects & Arthropods (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention provides immortalized tick cell lines, an immortalized bovine T cell line and uses therefor, including diagnostic reagents and vaccine compositions.
Description
:1, , " ~r ~VO 94/06463 ~ g 6 S 1 PCl/US93/08606 IMMORTP~T ~7Fn CELLS AND USES TH~REFOR
Field of the Invention This invention relates generally to il~ ~ ~lized pnmary cells, and, more specific~11y, to i~llnlul Lalized cell lines useful for the production of antigens and biologically active cv~ oullds.
P~aek~round of the Invention Continnous or immortalized cell lines which are chara~ten7ed by the ability to grow indto.finitely are valuable as a souree of immunogens, a source of new biologically active compounds and for the production and replication of relevantpathogens. The ability to establish a eulture that will grow indçfinitely variesdepending on the animal speeies from whieh the eells originate. For example, rodent eells routinely generate eontin~lous cell lines, but ehieken eells almost never beeome immortal. Human eells, with the exeeption of tumor eells, are not good sourees of immortalized eell lines.
Tick cell cultures are of interest for the research and study of tick-borne pathogens and microor~nism~ Presently available }n vitro primary or continuous tick cell cultures are not capable of long term, eonsistent maintenance of tick-borne
Field of the Invention This invention relates generally to il~ ~ ~lized pnmary cells, and, more specific~11y, to i~llnlul Lalized cell lines useful for the production of antigens and biologically active cv~ oullds.
P~aek~round of the Invention Continnous or immortalized cell lines which are chara~ten7ed by the ability to grow indto.finitely are valuable as a souree of immunogens, a source of new biologically active compounds and for the production and replication of relevantpathogens. The ability to establish a eulture that will grow indçfinitely variesdepending on the animal speeies from whieh the eells originate. For example, rodent eells routinely generate eontin~lous cell lines, but ehieken eells almost never beeome immortal. Human eells, with the exeeption of tumor eells, are not good sourees of immortalized eell lines.
Tick cell cultures are of interest for the research and study of tick-borne pathogens and microor~nism~ Presently available }n vitro primary or continuous tick cell cultures are not capable of long term, eonsistent maintenance of tick-borne
2 0 pathogens.
There exists a need in the art for imrnortalized vitro eell eultures of cells capable of supporting the growth of pathogenie org~nicmc, for use in developing vaccines to seleeted pathogens and for research purposes.
2 5 Summary of the Invention The invention provides imrnortalized cultures of primary eells. These cell lines are useful, for example, as ~ntigçns in vaecine compositions, as vessels for growth and production of antigens, as diagnostic reagents, and in therapeutic compositions.
There exists a need in the art for imrnortalized vitro eell eultures of cells capable of supporting the growth of pathogenie org~nicmc, for use in developing vaccines to seleeted pathogens and for research purposes.
2 5 Summary of the Invention The invention provides imrnortalized cultures of primary eells. These cell lines are useful, for example, as ~ntigçns in vaecine compositions, as vessels for growth and production of antigens, as diagnostic reagents, and in therapeutic compositions.
3 0 Other aspects and advantages of the present invention are described further in the following 3et~i1e~1 description of the preferred embotiimentc thereof.
Detailed Descl;u~ion of the Invention The present invention provides i~n~ alized tick cell lines and an 3 5 immortalized bovine T cell line. Such immortalized cell lines according to this invention are useful as, or in the production of, vaccinal agents, e.g., against ticks, and may provide protection against ~ise~es caused by pathogens, e.g., tick-bornepathogens.
WO 94/06463 2 1 ~ ~ 6 5 ~ PCr/US93/08~
As used herein, the term "i~ Ol L~lized cell line" refers to the cells depositedwith the ~m~ ~c~n Type Culture Collection (ATCC) as stated below. Immortalized cells of this invention may be clonally expanded by conventional techniques to produce a homogeneous population of progeny cell lines which can be m~int~ined 5 continuously in an appropriate culture m~ m Illlmol L~lized cultures of Dermacentor andersoni and Amblyomma amçricanum tick gut are provided. One example is the tick cell line called DGEC~This cell line, is describeA in detail and char~cteri7~d in Example 1. The line has remained stable for over 26 months and was deposited with the American Type Culture Collection (ATCC) on July 8, 1992 [ATCC Accession No. CRL 11084].
Also deposited with with ATCC on July 8, 1992 [ATCC Accession No. CRL 11083~, was the AGEC-1 imrnortalized tick cell line of the invention, which is discussedbelow in more detail.
Further, the invention provides an immortalized bovine T cell line, designated Bpbl-T1 (bovine peripheral blood lymphocyte-T cell). This immortalized bovine T
cell line is useful, inter alia, for T-cell dependent antigen targeting assays, T-cell receptor and antigen recognition studies, adoptive transfer experiments, and in vitro screening of cytokines, antigens and/or other bioresponse mo lifiers. This line has remained stable for over 8 months and was deposited with the ATCC on September 2 o l l , 1992 [ATCC Accessi~n No. CRL11120].
This invention further includes progeny and derivatives of these cell lines, e.g., cells which have been derived from the specific identified cell line by passaging or clonal expansion. All st~tements made herein relating to the il~ Ol L~lized cell lines of the invention are equally applicable to their progeny and derivatives.
2 5 Immortalized tick cell cultures of this invention are useful for, among other things, growing, in vitro, tick-borne pathogens, such as Borrelia burgdorferi. the causative agent of Lyme ~iice~ce~ and for producing antigens to these pathogens.These cell lines have also proven useful in m~int~ining vitro cultures of ~A.
marginale~ Fhrlichia species, and Borrelia bur~dorferi.
3 0 The immortalized T cells of the invention are also useful for growing a selected pathogen, as well as for producing antigens to these pathogens.
Additionally, the immortalized T cells of the invention are useful for the study of pathogens capable of infecting T cells, e.g. lentiviruses, and the study of T-cell signal transduction.
The i~ llulLalized cells of this invention provide a system for mass production of antigens, e.g., preferably cellular components such as proteins or non-proteinaceous material capable of inducing an immune response directed against a W O 94/06463 2 l ~ ~ G 5 1 PC~r/US93/08606 parasite borne pathogen. According to one embodiment, an immortalized cell of the invention may itself produce a biolog*al or therapeutic agent, e.g., a tick cellpolypeptide or protein, or another component or fraction of a tick cell which enh~nres the ability of a vaccine composition cnnt~ining a selected pathogenic 5 antigen to stim~ te a protective immune response in the vaccine. For exarnple, the o-lalized tick cell lines, AGEC-1 or DGEC-1, when cultured may naturally produce peptides, polypeptides, proteins, or other cellular fractions which are useful as anti-co~ nt~, anti-infl~mm~tnry agents and diuretics, for pharmaceutical and veterinary purposes. These exemplary and other agents are among the biological 10 products naturally produced by an imrnortalized cell of this invention upon culture.
Appropriate culture conditions to obtain maximum production of such natural products can be determined by one of skill in the art. These biological materials may be produced intr~cellnl~rly and obtained from the cultured tick cell by conventional cell disruption, e.g., lysis, and purification of the material or a cellular fraction 15 containing it from the lysate, based on its chPmiral identity or biological activity.
~ltrm~tively, the immortalized cell of the invention may secrete the agent into the media. Methods of isolating and purifying such biological materials or cell fractions are known in the art and may be utilized as desired.
According to another embodiment, the present invention provides a method 2 0 for producing antigens directed against a selected pathogen by infecting an imlllol Lalized cell culture of the invention with a selected pathogenic microorganism, e.g., ~3orrelia burgdorferi. Ehrlichia canis, Ana~ ma marginalis. Babesia bovis,Theileria parva. The infected iml.~ alized cell may, upon culturing permit the natural replication of the pathogen, and the production of pathogenic proteins in 2 5 culture. Either the pathogen itself, whether it be a virus or microorgani~m, or desirable proteinaceous m~trri~lc including subunits, polypeptides, cell fractions, fr~gmP,nt~ thereof, or other macromolecules such as carbohydrates, lipids, and lipoproteins may be produced in, and isolated from, the immortalized cell culture by conventional biological and genetic en ineering techniques. Such proteinaceous and 3 0 non-protein~reous materials, including the i~ lol ~lized cell or pathogen itself, are defined herein as antigens. Alternatively, the pathogens may be co-harvested from the cell culture infected by the pathogen.
It is understood that proteinaceous and non-proteinaceous materials produced by the pathogen-infected hlllllol ~lized cell lines may be include materials produced 35 from the immortalized cell biosynthetic activity. Pathogen-produced materialsisolated from the cell culture are expected to have use in vaccine compositions. For example, association of such pathogen-produced material with tick cell derived WO 94/06463 - `2 1 4 4 6 ~; 1 PCr/US93/0869 m~teri~l may provide vaccinal compositions with enhanced ability to stimnl~te immllnity in the vaccinee due to the influence of the tick cell environment upon the development and growth of the pathogen in the tick cell culture. In a similar manner, the illlll~Ul ~alized bovine cell line and products produced therein may be used to enhance vaccine compositions cont~ining bovine pathogens or antigenic materials t thereof. These cells and m~ten~l~ may further be of use in aiding identification of bovine antigens and in assaying for bovine cytokine production and activity.
Still an alternative embodiment for producing desirable antigens or polypeptides using an immortalized cell line of this invention involves transfecting the cell line with a recombinant molecule containing a heterologous polypeptide or protein having desirable antigenic properties under the control of a suitable regulatory sequence capable of directing the replication and expression thereof in the ihlllllolL~lized cell line. The transfected immortalized cell line containing the recombinant molecule is cultured to enable ~ ssion of the heterologous protein or polypeptide in the cell line. The methods employed in the design of the recombinant molecule, selection of the heterologous protein and regulatory sequences, and incorporation thereof into the cell line are within the skill of the art. [See, e.g., Maniatis et al., Molecular Cloning (A Laboratory M~mual), Cold Spring Harbor Press, Cold Spring Harbor New York (1989)].
2 0 Exemplary suitable vectors or plasmids for tr.msfecting the imlllol ~lized tick cells include those with an operational promotor, including insect viruses, insect recomhin~nt pl~mi(ls, Entomopox virus, and arboviruses. Currently, it is expected that insect promoters, such as polyhedron of baculovirus, spheroidin of entomopox virus, drosophila promoters or arbovirus (Semliki Forest Virus) would produce the 2 5 best results in the illllllOl Lalized tick cells. Similarly, vector components for m~mm~ n cells and known vectors may be readily selected by one of skill in the art for use in transfecting the bovine cell line Bpbl-Tl. See, for example, Maniatis et al, cited above.
The production of a desirable antigen from an immortalized tick cell line of 3 0 this invention is e~emrli~ l below (Example 3). Analogous procedures may beemployed to produce ~ntigens in the immortalized bovine cell line of the invention.
Media and cells from pathogen-infected illllllOl L~lized cells are generally collected at 24-108 hours post-infection and are used as the source of antigen for imm~lni7~tions.
If desirable, antigen-cont~ining media can be clarified from cell associated m~te~i~l by 3 5 centrifugation, aliquoted and stored at -20C until used. Alternatively, the pathogen ~ntigeniC m~teri~l may remain associated with any cell material from the imrnortalized cell and be incorporated into a vaccine. Immortalized tick cell produced material in ~094/06463 21~t651 PCI/US93/08606 association with the seleGte~l pathogen antigen may enhance the immunostim~ tQryeffect of the pathogen antigen. All antigen preparations can be quantified for parasite-specific protein (PSP) with ELISA. Cell-associated antigen may be prepared by sonication on ice in serum-free media followed by the centrifugation step 5 described above. Protein concentrations are determined by the method of Bradford, Anal. Biochem.~ ~:248 (1976). Sonicated parasite suspensions are adjusted to a final concentration of 10-100 ~lg/mL in serum-free media, aliquoted, and stored at -20C
until use.
The pathogens may express receptors on the cell surface of the illllllOl L~lized10 cell of the invention or intracellularly. Alternatively, the pathogens are contained intr~cell~ rly and released when the immortalized cell is disrupted in vitro or is processed in vivo by the animal vaccinated with the pathogen-containing immortalized cell. Disruption may be accomplished using known means, e.g. by freeze-thawing or other biochemical or mechanical disruption. In still another 15 alternative, antigenic portions of the pathogen are purified or left in combin~tion~ i.e.
the antigens may comprise a mixture of unpurified cellular material, viral subunits or fr~gmentc, media, and, optionally an adjuvant, from the imlllol~lized cell in which they are produced and used in a vaccine formulation.
The antigens produced as described above can be employed in the preparation 2 0 of a vaccine. The vaccine comprises an immunogenic amount of one or more antigen produced by the invention in a form suitable for internal ~(iministration.
Such a vaccine, directed against the selected pathogen or parasite, comprises an immunogenic amount of at least one pathogenic antigen which is produced by growing an immortalized cell culture of this invention infected with the selected 2 5 pathogen, including viruses and microorganicmc. The pathogenic antigen, as defined above, includes the entire pathogen, desirable subunits, polypeptides, cell fractions or fr~gmentc thereof, or desirable non-proteinaceous material.
Alternatively, the vaccine contains a whole in mortalized cell and the pathogen antigen. The pathogenic a~ntigen may be expressed in the i~ alized cell3 0 intracellularly, on the cell surface, or secreted during the natural processing of the cell or a vaccine fc)rmlll~tion containing a pathogen-infected hlllllollalized cell by the host. ~ltern~tively, such a vaccine composition may contain some cellular component of the immortalized cell which is not the whole cell, e.g., an irnmunogenic protein or polypeptide fragment of the immortalized cell, a subunit non-proteinaceous 3 5 material, or mixtures thereof.
In another embodiment, a vaccine is designed to protect against a tick. Such a vaccine composition contains an immunogenic amount of an immortalized tick cell _, 7, -- 6 5 1 of the invention, a cellular fraction, an antigenic protein or fragment of the cell, or other suitable immllnogenic fragments of an i~ o~lized cell of the invention. Inanother embodiment, the anti-parasite vaccine of the invention may contain both of the immortalized tick cell lines of the invention, or combinations thereof, whether as 5 whole cells, cellular fractions, or only proteinaceous or desirable non-proteinaceous materials from the cells. Further, these vaccine compositions may include other conventional anti-parasitic agents suitable for internal ~lmini~tration and/or be ~-lmini~tered in connection with other, known tick vaccinal compositions. Example 2 illustrates cross-species reactivity with an anti-tick vaccine of the invention.The AGEC-1 and DGEC-l immortalized tick cell lines of the present invention and the Bpbl-T1 bovine cell line are used to prepare vaccines with or without incorporated and replicating pathogens (See Example 3) and a pharmaceutically acceptable carrier. For example, as a tick vaccine, the uninfected or non-pathogen associated tick cells are replicated to the desired volume and cell15 density using large scale cell culture procedures known to those in the art such as (e.g., roller bottles, microcarrier, suspension, hollow fiber, etc.). The cells are harvested by standard procedures and concentrated by ultrafiltration or centrifugation. The cells are inactivated by 1-3 cycles of freeze-thaw, or heat or suitable chemical inactivation. The inactivated cells are then adjuvanted under 2 0 optimal conditions to provide a suspension of cells and adjuvant. The bovine cells may be analogously manipulated for the preparation of a vaccine composition.
In another formulation, the membrane proteins of the immortalized cells harvested can be fractionated by standard methods to form a vaccine containing only a part of the immortalized cell of the invention alone or in combination with other 2 5 antigens. This vaccine would not need an inactivation step, but may optionally be adjuvanted and arlminictçred in the manner described above. Similarly, one of skill in the art can identify desirable immunogenic proteins, peptides, or polypeptides derived from an i~ lized cell of the invention for inclusion in a vaccine composition ofthe invention. Such proteins, peptides, or polypeptides once iclentifie A can be3 0 isolated and purified, produced recombin~ntly, or synthesized by known means.
Vaccines of this invention may be employed in a method of immnni7ing hum~ns or anim~ls against a selected pathogen by injecting a vaccine of this invention into the animal.
As one example, a vaccine composition may contain as one of its active 3 5 ingredients a selected Borrelia antigen produced in cell line AGEC- 1 or DGEC-1, and either purified from the cell line or used in association with cellular material from the tick cell line. Such a vaccine is desirably ~mini~tered to humans and animals to ~O 94/06463 2 1 4 4 6 5 1 PCI/US93/08606 stim~ te ill " "llllily against Lyme disease or ticks. Where the vaccine comprises Borrelia antigens only, the vaccinee may develop ;"",~,.;ly against the spirochete, the causative agent of Lyme ~lice~e Where the vaccine also contains tick cell antigenic m~t~ri~l, the vaccinee may develop an immune response which destroys the tick - 5 before it can transfer the spirochete to the vaccinee. In the same manner, a vaccine of this invention can be used to protect against Rocky Mountain spotted fever, Ehrlichiosis, arboviruses, anaplasmosis, theileriosis, babesiosis, cutaneous irritations, and allergic dermatitis, where the antigen produced in the cell line is derived from one of the pathogens causing that condition.
~ltern~tively, where a vaccine of the invention is form~ te-l to be protective against Lyme tli~e~e, the whole immortalized tick cell, or a cellular fraction or subunit, a tick cell protein or peptide fragm~nt, or combin~tion thereof, from the immortalized cells may provide one vaccine component to stim--l~te immllnity to the tick cell. A tick cell vaccine component may be separately ~rlmini~tered with a vaccine containing a whole, inactivated pathogenic cell or subunit vaccine prepared from Borrelia. In other words, the Borrelia antigen does not have to be produced in the immortalized cells. It may be produced in another conventional way and co-~rlminictered with an immortalized tick cell component-containing composition.
Alternatively, in the present invention, Borrelia are grown in the immortalized cells 2 0 and then the entire il~ ol ~lized cells and spirochete material are harvested, inactivated, and preferably adjuvanted as described above. Another embodiment involves se~ting the spirochete or spirochete-produced proteins or antigenic fragments from the immortalized cells after growth and preparing the spirochetes or proteinaceous fr~gm~nts separately from the cells as a vaccine. In this case, the 2 5 spirochete is inactivated, or a protein isolated and adjuvanted in a similar manner.
Thus, the present invention provides a vaccine useful in preventing infection with any tick-borne pathogen. Such a vaccine composition contains an immortalized tick cell of the invention, or an immunogenic or antigenic fragment thereof, and an antigen directed to the selected pathogen. This antigen may be a whole inactivated 3 0 viral or cellular pathogen, or an antigenic protein, macromolecule or polypeptide thereof. For example, in a preferred embodiment, an anti-Lyme disease vaccine contains both the immortalized cells and any Borrelia bur~doferi antigen. An example of such an antigen is the spirochete, described in Example 9. However, this invention is not limited to an antigen produced in association with the illllllOI lalized 3 5 tick cells of the invention, but the Borrelia antigen may be obtained from other sources. It is anticipated that such a vaccine would offer superior protection over a vaccine containing solely the spirochete or subunits thereof.
WO 94/06463 2 1 ~ 4 6 5 1 PCI/US93/0861~
~. .
An immortalized cell of the invention can also be used as a recombinant vector for expression of a gene from a selected pathogen, e.g., Borrelia. Thus the need for growing and m~int~ining the spirochete would be elimin~t~rl Such a recombinant veetor expressing the gene for Borrelia is introduced into the immortalized tick cells. The tick cells e~lt;s~.ing the gene are harvested as described above, inaetivated, adjuvanted, and optimiæd for stability and efficaey.
For example, certain Borrelia express outer surface proteins (OSPs) which are capable of dir~elllially distinguishing between Borrelia grown in standard laboratory media and Borrelia passaged through live ticks. Using a recombinant DNA
approach, genes representing the OSPs from Borrelia vectored by live ticks could be isolated and expressed in an ap~ iate vector. Particularly useful vectors include the Semliki forest virus vector, the baeulovirus vector and the entomopox virus vector. The ill~lllulL~lized tick cells of the invention, infected with these viruses to produce the desired antigen are processed as whole cell or subunit extracts as described above.
Typically, antigenic proteins produced in association with the imrnortalized cells of this invention are desirably employed in vaccine compositions. For example, an immunogenic amount of an antigenic protein or desirable non-proteinaceous material are mixed with a ph~Tm~eutically acceptable carrier. An immunogenic 2 0 amount of a selected pathogenic antigen is generally between about 0.01 llg to 10.0 mg antigen, more preferably 0.05 ~Lg - 1 mg, and may be determined by one of skill in the art depending on the identify of the antigen, pathogen, and host animal.
An imm~lnogenic amount of the illlmollalized tick cells is about 101 to 108, and preferably about 106 cells/dose. Alternatively, the total immortalized cell 2 5 proteinaceous material, cellular fractions, or desirable non-proteinaceous macromolecules is in the range of 0.05 llg to 1 mg, as described above for the pathogenic antigens above. However, one of skill in the art ean make appl.,pliate adj~lstm~t~ depending upon the vaecine.
In adrlitiQn to the aetive ingredients discussed in the preeeding paragraphs, 3 0 other optional ingredients inelll-ling, for example, stabilizers, e~riers, and adjuvants may be added to the vaccine compositions of the invention. Stabilizers are addedoptionally to provide longer shelf life or enhance the poteney of the forrn~ tedvaecines of the invention. Typieally, stabiliærs, adjuvants, and inaetivation agents are Optil~ ed to determine the best form~ tion for efficacy in the target animal.
3 5 Suitable stabilizers, as with the other op~ional ingredients, are well known to those of skill in the art. Examples of such st~bili7ers inelude e~c~mino acids, sucrose, gelatin, phenol red, N-Z amine AS, monopotassium glllt~m~te, potassium ~0 94/06463 PCI/US93/08606 ~1~4651 monophosphate, potassium diphosphate, bovine albumin fraction V, lactose, lactalburnin hydrolysate, dried milk, and heat inactivated serum.
Suitable ph~rm~ceutically acceptable carriers facilitate ~tlmini~tration of the proteins and antigens but are E3hysiologically inert and/or nonharmful. Carriers may 5 be selected by one of skill in the art. Exemplary carriers include sterile saline, lactose, sucrose, calcium phosphate, gelatin, dextrin, agar, pectin, peanut oil, olive oil, sesame oil, and water. Additionally, the carrier or diluent includes a time delay material, such as glyceryl monostearate or glyceryl distearate alone or with a wax. In addition, slow release polymer formulations can be used.
The vaccine compositions of this invention may be incorporated into convention~l sustained-release matrices, implant formulations, tablet formulations or injectable sustained release formulations and matrices. Components of such formulations are well known to the art.
One or more of the above described vaccine components may be admixed or adsorbed with a conventional adjuvant. The adjuvant is used as a non-specific irritant to attract leukocytes or enhance an immllne response. Such adjuvants include, among others, mineral oil and water, aluminum hydroxide, Amphigen, Avridine, L121/squalene, D-lactide-polylactide/glycoside, pluronic polyols, muramyl dipeptide, killed Bordetella. saponins, saponin-derivatives such as Quil A, and Immune 2 0 Stimul~tory Complexes (ISCOMs).
Inactivation agents may also be included in the vaccine formulations of the invention. Suitable inactivation agents include formalin, glutaraldehyde, binaryethylçneimine (BEI), beta-propriolactone, and heat, and freeze/thaw techniques. Other suitable agents are well known in the art.
A desirable dosage of a vaccine of the invention involves the ~lministration of 1 to 3 doses of desired vaccine composition, where the desired antigenic content of each fraction is as stated herein. The vaccine is preferably ~tlmini.ctered in two injections intramuscularly or subcutaneously, approximately 2 weeks to 3 months apart to immllni7e and boost the immune system of the target animal. However, the 3 0 mode of ~ministration of the vaccines of the invention may be any suitable route, including intradermally, intravenously, intraperitoneally, transdermally, topologically (e.g. by patch ointment) and by implant.
The specific dose level, mode and timing of aflmini~tration for any particular animal depends upon a variety of factors including the age, general health and diet of 3 5 . the animal; the species of the animal; and the degree of protection being sought. Of course, the ~lmini~tration can be repeated at suitable intervals, such as annually, if necessary or desirable.
21~6~:~
W O 94/06463 `~ PC~r/US93/086 For example, in cattle, the volume of the dose may vary from 0.1 to ~ mL of a sterile preparation of an immunogenic amount of the active vaccine component or co~ onents to 0.1 to 1 mL in a small animal such as a dog or cat. The immnne measurements to detect active immnni7~tion of the t~rget animal can be determined 5 by testing titers of antibody to cell protein using vitro detection systems such as ELISA.
In another aspect, the immortalized cells of the invention may provide si~ni~lc~nt thel~peuLic products. The ap~ liate me~linm and other conditions under which to culture an illlll~l L~lized cell line of this invention to enable it to produce a 10 desired therapeutic agent can be readily determined by one of skill in the art by conventional techniques. Such a therapeutic agent may be secreted directly into the culture medium and isolated by conventional techniques by one of skill in the art.
~ltern~tively, if expressed internally, the agent can be isolated from a culture lysate of such cells using known techniques.
Thus, the present invention also provides a method of immllni7ing animals against tick infest~tion, Lyme rlise~e, and other tick-borne diseases by ~lmini~tering to an animal a vaccine compostion of the invention. For the method of hl,mu"izing ~nim~l~ against tick infestation, the vaccine composition of the invention contains an immunogenic amount immortalizing tick cell of the invention, DGEC- l, AGEC- l, 2 0 progeny or derivatives thereof, or combinations of these cells. For the method of ir~ ing animals against Lyme disease, the vaccine composition of the invention may contain an immunogenic amount of one or more B. bur~dorferi antigen produced in, on, or by an illllllc,llalized tick cell line of the invention, an immortalized tick cell line of the invention alone or in combination with one or more ~3. burgdorferi antigens, or a combin~riQn of these.For the method of immnni7ing ~nim~ls against a selecte~l tick-bome ~lise~e, the vaccine composition of the invention may contain an immnnogeniC amount of one or more antigen from the pathogen which causes the tick-bome disease produced in, on, or by an illmlol~alized tick cell line of theinvention, an immortalized tick cell line of the invention alone or in combination with 3 0 one or more of the pathogen, or a combination of these.
The present invention further provides a method of immuni7ing animals against a selected pathogen, where said pathogen is capable of being grown in association with the immortalized bovine T cells of the invention. In par~cular,bovine lellk~mi~ virus, bovine immunQdeficiency virus or other pathogens which 3 5 infect bovine lymophocytes are anticipated to be suitable pathogens for growth in the c Bpbl-Tl i~llmol~lized bovine T cells:
~ro 94/06463 2 1 ~ 4 6 5 I PCr/US93/08606 The imrnortalized cells of the invention also provide a source of diagnostic reagents. For example, the DGEC-1 or AGEC-1 i~ ol~lized tick cell lines of the invention, or preferably protein sequences thelc;Lulll, may be used as diagnostic reagents in an in vitro assay to detect the presence of a pathogen, particularly a tick-borne pathogen, in a sample of body fluids from an animal suspected of infection. In addition, pathogens produced in the immortalized cells of the invention, and their protein sequences may also provide diagnostic agents for the pathogen. Further, the specificity of the illllllOl ~alized cell receptors can be used to determine typing of org~nicmc isolated from patients suspected to have been exposed to such org~nicms.
1 0 Once the ,cce~ is identified, receptor specific typing can be performed.
Such a diagnostic assay preferably involves the association of the cell line of the invention with a detectable label and the incubation of this diagnostic reagent with the sample fluids. For example, the specificity of the receptors on the immortalized tick cell sof the invention, can be used to type org~nicmc isolated from patients suspected of being bitten by a tick. Because the DGEC- 1 cell specifically agglutinates strain 297 of Borrelia burgdorferi~ agglutination could be used to type other B. burgdorferi strains. Binding of a pathogen to the cells can be detected by a variety of conventional assays, including agglutination, amplification, stim-llRtion of a pathogen antigen, e.g., OSP on Borrelia, and competition binding lltili7ing a MAb to 2 0 the pathogen, e.g., Borrelia, or a receptor on an immortalized cell line of the invention.
In one embodiment, B. bur~dorferi specifically agglutinates after attachment to DGEC-1 cells in vitro, intlic~ting a specific receptor on tne B. burgdorferi and DGEC-1 cells. After several days of attachment, the B. burgdorferi are inducecl to 2 5 replicate. Normally, B. burgdorferi will not replicate in DGEC- 1 media. The binding, ag~lutin~tion and det~chm~nt denotes an activation (synergy) step between B. bur~dorferi and DGEC- 1. Thus, the immortalized cells and/or B. burgdorferi may elaborate growth factors in the media.
Antibodies to a receptor(s) on the il~l,lol~lized tick cell lines of the invention, 3 0 DGEC- 1 or AGEC- 1, may be used in diagnostic assays. Conventional techniques for making suitable polyclonal, recombinant, or more desirably, monoclonal antibodies are well known to those of skill in the art [see, e.g., Kohler and Milstein; W. D. Huse et al., Science. ~ 1275-1281 (1988); PCT Patent Publication No.
PCT/W086/01533, published March 13, 1986; British Patent Application No.
GB2188638A, published October 7, 1987; Amit et ~1-, Science~ ~:747-753 (1986);
Queen et al., Proc. Natl. Acad. Sci. USA~ ~:10029-10033 (1989); PCT Patent Publication No~ PCT/WO90/07861, pubiished July 26, 1990; and Riechmann et al., 21~551 WO 94/06463 ; ~ ; PCr/US93/08 ~ature, ;~:323-327 (1988)]. For ~ gnostic purposes, the antibodies may be associated with individual labels, which are preferably interactive to produce adetectable signal. Most preferably, the signal is visually detectable. For colorimetric detection, a variety of enzyme systems have been described in the art which will5 operate ap~lop~;ately.
Antibodies specific for receptors on DGEC-l or AGEC-1 may also be used therapeutically as targeting agents to deliver therapeutic compounds. Rather than being associated with a label, such a therapeutic agent employs the antibody linked to an agent or ligand capable of disabling the replicating mechanism of the pathogen.
10 Alternatively, the antibody may block binding of the pathogen to the target cell.
Such antibodies may also be useful in therapeutic compositions for treating tickinfestations.
The following examples are merely illustrative of the different aspects of this invention and are not intended to limit the scope of the present invention.
F.xample 1 - Characterization of Transforrned Cell Line The im~lloll~lized cells DGEC-1 derived from the intestinal epithelial tract of Dermacentor andersoni show continuous growth and replication by a budding process, which can result in "chain-like" clusters of cells. Growth characteristics 2 0 change with increased duration in culture. However, replication rates among gut cells transformed according to this method vary, as does the ease of transformation.
At approximately nine months after initiation of cultures, the cell replication rate increased and slight morphological changes occurred. A distinct nucleus became visible for the first time. It is possible that cells required this time to accommodate to 2 5 culture conditions and to delete transfected DNA, which is not needed for cellular growth and development.
Three types of cells have been observed in the heterogeneous population:
small, round and clear; large, granular and brown; and large clear cells. Cells possess phagocytic activity throughout the culture period. ~ntimif~robials have been removed 3 0 from est~bliche~l cultures without any detectable changes in cellular growth characteristics.
The DGEC-l cell line was further characterized by (1) selective ~tt:~chment by Borrelia burgdorferi (receptor metli~tor), (2) differential phagocytosis of red blood cells in mixed blood cell populations and (3) induction of immnne response in guinea 3 5 pigs that reduced tick infestation and feeding. The line has remained stable for over 15 monthc.
~ro 94/06463 2 1 g 4 6 5 1 PCr/US93/08606 Further, this cell line, as well as illll~lUl ~lized intestinal epithelial cellsfrom ,~mblyomma ~rnericanum (AGEC-1), have proven useful in maintaining in vitrocultures of A. n~ ale. ~, bur~dorferi. and F~hrlichia species. It is expected that these cell lines will also be useful in maintaining in ViVO cultures of Arboviruses, 5 Babesia, and other tick-borne pathogens.
The growth of certain of these pathogens is demonstrated in Example 3 below.
Exarnple 2 - Immunization of Guinea Pi~s with Il--n~ol lalized Tick Gut cells Successful vaccination of guinea pigs with tick gut extracts is always accompanied with a specific antibody titer than can be enhanced upon repeat vaccinations. These antibody titers are normally measured by ELISA tests. To determine whether the immortalized gut cells have retained the ability to synthesize important antigens for immunological control of ticks, the cells were used to vaccinate guinea pigs. Three ~al~lllcters are used to ~letermin~ whether the guinea pig has been successfully immllni7eA against tick infestation: (a) death during or shortly after the blood meal is taken, (b) reduction or elimin~tion of ovipositing (egg laying), (c) reduction or lack of hatching from egg mass that is laid. These parameters are additive in the clinical measurements against tick infestation since any 2 0 can block the tick life cycle. This example describes the results of vaccination and challenge studies in the guinea pig model and demonstrates production of antibody against the immortalized tick cells that cross react with native tick gut tissue in an ELISA format.
The continuously growing tick gut cells of the invention were harvested from L-15B complete medium, centrifuged (at 150 x g; 10 minutes), and washed 3x in L-l5B incomplete ..,~li-.... The cells were then resuspended in L-15B incomplete medium and adjusted to 1.0 x 106 cells/mL. One million cells were a~lmini~t~red by subcutaneous injection to each guinea pig on days 0 and 14. Each injection was in a volume of 1 mL, and given in a dose divided between two sites. A total of 12 guinea 3 û pigs: 6 for Amblyomma americanum cells and 6 for Dennacentor andersoni cells were used. Two weeks after the last injection of cells, the ~nim~l~ were bled bycardiac puncture, 4 mL of blood from each animal was collected, serum separated and stored at -20C. Tmmllni7ed ~nim~l~ developed strong antibody responses as determined by enzyme linked immunosorbent assay (ELISA) as described below.
3 5 The antigen was prepared as follows. Adult, female, unfed DelTnacentorandersoni and Amblyomma americanum (200 each) were surface sterilized and their gut tissue was collected in sterile PBS (pH 7.2, 0.15 M). The gut preparation was W0 94/06463 2 t ~ Bsl PCl/US93/08 sonic~te~ and the protein content det~rmined by bicinchoninic (BCA) assay as described in P. K. Smith et al, Analytical Biochernistry. 150:76-85 (1985).
The coating for the wells was made up of 5 ~lg/mL of gut antigen suspended in carbonate-bicarbonate buffer, loaded 100 ~Vwell, and incubated at 4C overnight.
5 The wells were blocked with 1 % bovine serum albumin.
Serum dilutions (both control and immune) were made from 1:10 to 1:20480.
The second antibody used was rabbit anti-guinea pig (IgG, H&L) in HRPO, 1: 1000 in 1% BSA (PBS, 0.05% Tween-20). The substrate was o-phenylene dramine [OPD;
Eastman Kodak, Rochester, NY] and the optical density was read at 490 nm. The 1 0 results of these assays are set out in Tables 1-3 below.
Tables 1 and 2 set out the results of an assay performed on guinea pigs immllni7ed with Amblyomma americanum gut cells ill-l,lol~alized by the techniquedescribed in Example 5 above. The native gut antigen (5 ~Lg/mL) was 500 ng/well in 100 ~LL-as determine~ by enzyme-linked immunosorbent assay, ELISA, using known 1 5 techniques. Tick gut protein concentrations were deterrnined prior to testing as a standard. Each well was coated i~le~tir~lly, each using the same antibody dilution and detector antibody. Labelled antibody was rabbit anti-guinea pig-HRPO (IgG, H&L), 1:1000. The pre-imml-ni~tion titers (OD160) of A. americanum antigen were 0.037 and of D. andersoni antigen were 0.064.
2 0 Table 1 represents the detennin~hon of antibody response in anim~ls imml-ni7P~l with irnmortalized A. americanum cells (AGEC-1) and not challenged with ticks. The time periods indicate the time after inoculation at which the sera was tested. The antigen refers to the antigen used in the test.
2 5 Table 1 FIVE WEEK POST-INJ. S~X WEEK POST-INJ.
NATIVE GUT ANTIGEN NATI~E GUT ANTIGEN
Guinea Pi~ Amblyomma l:)ermacentor Amblyomma Dçrmaçentor 1009 1.313 1.187 1.267 1.306 1010 1.144 1.036 1.230 1.292 1011 0.687 0.785 1.064 1.047 The following data represents the deterrnination of antibody response by ELISA in animals immnni7ecl with immortaliæd A. americanum cells and which were 3 0 tick challenged.
~Vo 94/06463 2 1 4 4 S ~ii 1 PCr/US93/08606 Table 2 NATIVE GUT ANTIGEN
Guinea Pi~ Amblyomma Dermacentor 1018 0.326 0.340 1019 0.545 0.667 1020 0.459 0.711 1021 0.381 0.203 1022 0.303 0.429 1023 0.461 0.613 Single cell suspensions were prepared from D. andersoni freshly isolated gut.
5 The isolated cells were frozen and thawed. Guinea pigs were imm~ni7e~l with this preparation at 0.5 mg per mL per animal. A total of three booster injections were given with a 10 day interval between inoculations. As can be seen from the data in Table 3 below, ~nim~l~ immllni7ed with the immortalized ~ermacentor andersoni gut cells (DGEC-l) developed strong antibody responses. The antigen of Table 3 is that 1 0 used for screening.
Table 3 NATIVE GUT ANTIGEN
Guinea Pi~ Arnblyomma l:~ermacentor 1024 0.167 0.343 1025 0.208 0.334 1026 - 0.160 0.442 1027 0.617 0.947 1028 0.495 0.458 1029 0.485 0.468 1 5 The antibodies generated against freshly prepared tick gut tissue by imm-lni7~tion of guinea pigs were used in immllnofluorescence assays to detect reactive epitopes on immortalized tick gut cells m~int~ine~l in culture for 11 months.
These guinea pig antibodies were obtained from animals that were subsequently challenged with ticks. After collection of sera for immunoloc~l;7~tion, immnni7e~
2 0 anim~lc were challenged with larvae, nymphs or adults of the sen~iti7ing species.
This immunolocalization data correlates with the protective study results.
WO 94/06463 2 1 4 ~ ~'1 PCI/US93/086~
Table 4 below illustrates the effect on the life cycle patterns of Dermacentor andersoni ticks on control ~nim~l~ and may be con.~a,ed with Table S which illustrates similar data on animals immllni7~d with Dermacentor andersoni native gut antigen.
Table 4 ~infest/ Feeding Physical *replete davs Wei~ht Dead/live Appearance Larvae 280/275 4 5/275 Hatched Nymphs 60/60 6 0/60 Molted Adults 8/8 8-10 946 mgs* 0/8 1034 mgs*
1023 mgs*
943 mgs*
1045 mgs*
988 mgs*
1038 mgs*
1011 mgs*
Table 5 ~infestl Feeding Dead/ Physical ~replete davs Wei~ht live Appearance Larvae 230/216 4 14/216 Adults 8/4 18-19 392 mgs 4/4 435 mgs 643 mgs 572 mgs This data shows that animals ;,.",~ni,ed with freshly prepared D. andersoni gut cells were resistant to infestation with adult ticks. None of the four female ixodids allowed to infest ;.~ i7efl guinea pigs produced ova, inrlicating a clear anti-1 5 tick response.
Tables 6 and 7 below illustrate this effect on Amblyomma americanum and Dermacentor andersoni ticks in animals immllni7Pd with Amblyomma americanum gut cells immortalized by the technique described above.
~VO 94/06463 2 1 ~4 6 51~ PCl/US93/08606 Table 6 - ~. americanum ticks #infes~/ Feeding Dead/ Physical #replete davs ~k'E~ li~ A~pearance Larvae 220/253 4 228 mg/0.9 mg nl Molted Nymphs 60/4~ 6 572 mg/12.71 mg n' Molted 1019 (75.0%) Adults 1020 8/8 12 23 mg 12 434 mg Dead Reddish 13 690 mg Reddish 14 55 mg Dark red 19 35.6 mg Dead Dark red 19 34.8 mg Dead Dark red 19 15.6 mg Dead Dark red (100 % dead) n1 (100% fed larvae survived) n2 {45 Molted to adults (7S.0%), 15 dead (25.0%)}
The red color indicates that the tick guts apparently rlicintegrated. One tick burst in capsule. The adult ticks in this study either died or were incapable of laying eggs. None produced egg mass.
WO 94/06463 2 1 ~ 4 6 5 1 PCI/US93/089 rable 7 - D. andersoni ticks #infest/ Feeaing Dead/ Physical #re~lete davs Weight ~ A~earance Larvae Nymphs 60/52 8 1421 mg/27.33 mg 23/29 29 grey 1022 (86.7%) nl 23 black Adults ~Eick) (E~ Mass) 1023 8/8 12 485 mg 244.9 mg* Dark red 12 792 mg 523.0 mg Grey 12 579 mg 358.6 mg* Grey 13 786 mg 465.8 mg Grey 13 539 mg 235.9 mg Grey 13 405 mg 198.9 mg Grey 14 498 mg 323.6 mg Grey 250 mg Grey nl { 17 molted to adult (28.3%), 43 dead t81.8%)) 5 * For the adults, in~licates that the ova produced by females did not hatch.
The lack of data for larvae inclic~tes that they did not attach to the host.
However, while there was no feeding, a severe cutaneous reaction was seen at thebite site. No egg mass was produced for those feeding 15 days. The data further 10 in~1ic~tes that the i~ i7~tion induced cross-species protection which is indicated by longer times to replete, lower finished weight and reduced viable egg mass.
Tables 8 and 9 below illustrate this effect on Amblyomma americanum and Dermacentor andersoni ticks in animals il~ lul-i~;d with il....lol~lized Dermacentor andersoni gut cells obtained by the technique described above.
~0 94/06463 PCI/US93/08606 Table 8 - 1~). andersonl t~
#infest/ Feeding Dead/ Physical #rçplete davs Weight live Appearance Larvae:
Nymphs:
1025 60/38 8 1058 mg/27.84 mg nl 31 grey (63.3%) 7 black Adults:
1026 8/6 12 768 mg dead black 12 972 mg dead dark red 12 791 mg* grey 12 936 mg** grey 13 970 mg dead reddish 19 15.6 mg grey nl {25 molted to adults (41.7%), 35 dead (58.4%)}
5 * Tn-lic~tes the production of egg mass (324.6 mg), which did not hatch.
** Tn~ ates the production of 353.5 mg egg mass.
Two ticks died early during feeding period. The lack of data for larvae indicates that there was no attachment. However, while no feeding occurred for 1 0 larvae, a severe cutaneous reaction was seen at the bite site.
_ WO 94/06463 2 1 4 ~ 6 S 1 PCI/US93/08~
Table 9 - A. americanum ticks ~infest/ Feeding Dead/ Physical ~replete ~ Weight 1~ Ap~earance Larvae 200/210 4 174 mg/0.83 mg Molted Nymphs 1028 60/38 6 366 mg/9.63 mg all grey {37 molted to adults (61.7%), 23 dead (38.4%)}
Adults 1029 8+8 14 296 mg dark red 14 370 mg* grey 14 417 mg** grey 276 mg dead black 18 158 mg dk grey 18 315 mg dk grey 19 37.5 mg grey 19 23.4 mg dead black * Indicates production of 131.5 mg egg mass.
5 ~* Tnclic~tes the production of 167.4 mg egg mass.
Anirnals immnni7e~ with immortalized cells were challenged with larvae, nymphs or adults of the homologous species. Prelimin~ry observations indicated that resistance to adult and nymphal challenge was present. Adult ticks required longer to 0 feed and engol~,e~ t was altered. Many male, female and nymphal ticks died after engorgement. In addition, production of ova was reduced. Immortalized digestive tract cells of ~. americanum appear to srimlll~te a more solid resistance to infestation than cells of D. andersoni origin.
This data indicates that the immun;7~tion induced some cross-species 1 5 protection.
Exam~le 3 - Growing Patho~ens in Immortalized Tick Cells A. Ehrlichia canis and Granulocytic Canine Ehrlichia Both Ehrlichia canis and Granulocvtic canine Ehrlichia (GCE) have been successfully grown in the illlll~ol~alized gut cells of Derrnacentor andçrsoni 2 0 (DGEC- 1} and Arnblyomrna arnericanum (AGEC- 1). The Ehrlichia was obtained from peripheral blood collected from dogs which were exp~rimellt~lly infected with these or~ni~m~. ~ canis is associated with lymphocytes and monocytes. GCE is associated with granulocytes. The peripheral blood was collected in vacutainers .
cont~lnlng hepann.
~O 94/06463 2 1 4 4 6 5 1 PCr/US93/08606 Peripheral blood lymphocytes (PBL) were isolated by Ficoll gradient (Histopaque) and washed 3x in L-lSB incomplete me~ m The cell numbers were then adjusted to 1.0 x 106 cells/mL and added to a flask containing gut cells (6 mL) (a few erythrocytes also were present in the peripheral blood lymphocyte 5 preparations.
Granulocytes were isolated from blood by the method described by Sigma Chemic~l~ using Histopaque 1077 and 1119 in a double gradient method.
Isolated granulocytes were washed 2x in L-15B incomplete medium inoculated to gut cells (1.0 x 106 cells/mL).
1 0 Microscopic ex~min~tion of cultures 2-3 days post infection showed aggregation of PBL/granulocytes around the gut cells. This was very evident in Amblyornma americanum gut cells, since they are big, oval and larger than PBLs/granulocytes. About 2-3 weeks post-inoculation, the cont~min~tecl RBC
degenerated, PBL/granulocytes showed rough surfaces and numerous granular 1 5 m~t~ri~l was observed in cultures. In addition, Amblyomma cells showed phagocytosis of hemoglobin (appeared red in color).
Eight to ten weeks after infecting cells, the minute bodies increased in number and many of these bodies studded on to the surface of the gut cells, particularly on Amb~yomma americanum gut cells. Diff-Quick stained culture smears 2 0 and one micron thin sections (toluidine blue stained) showed numerous bodies (lawn of uniform bodies), which were also studded on the surface of the gut cells.
Serum samples collected from dogs suffering from Ehrlichiosis were used as a source of antibody and used to identify the or~"ni~m~ in cultures by Florescent Antibody Test. Acetone fixed smears of culture were reacted with 2 5 antibodies to Erhlichia. and these immunoglobulins were localized by fluoroscein isothyocyante (FITC) conjugated anti-canine antibodies.
Cultures with material from infected dogs displayed reactivity. Immortalized gut cells had the appearance of being studded with minute fluorescent bodies.
B. P~orrelia bur~dorferi 3 0 Borrelia bur~dorferi strain 297 [SmithKline Beecham Animal Health]was grown in conventional BSK-II medium according to known techniques. Strains B31 [SmithKline Beecham] and SH-2-82 [National Institutes of Health] of B.
r burgdorferi have also been established. Two vector competent strains include 27985, isolated from I. d~~ filli in Stamford, Connecticut, and 21305, which was isolat ed from Peromysus leuco~us [both of which are available from John Anderson, Connecticut Agricultural Resource Station~. However, other, known, strains of B.burgdorferi may be used.
WO 94/06463 2 1 ~ 4 6 5 1 PCr/US93/08~
An 8-10 day old culture of B. burgdorferi strain 297 (200 ~L) was added to each of two T-25 flasks. Dermacentor andersoni irllllwl L~lized gut cells (DGEC-1) and Arnblyomma americanum immortalized gut cells (AGEC-l) were cultured in antibiotic-free L-lSB complete m~illm 24-48 hours prior to inoculating 5 with the spirochetes. The spirochete infected tick cell cultures were incubated at 30 C in a dry incubator as described below.
1. Dermacentor andersoni The spirochetes started attaching to the cells by 24 hours post infection. As the incubation continlle(1, the clumping of cells by spirochetes 10 increased. By 4-5 days post infection, clear entanglement of cells by spirochetes was evident. It was observed that the cell types in the culture, small, round, clear gut cells were att~cked by the spirochetes. The large, round, brown color cells may be resistant to spirochete attachment. By 10-12 days post infection, the spirochetesensitive cells were disintegrated and only spirochete resistant cells were present in 15 the culture. By 15 days post infection, the so-called spirochete resistant cells started multiplying and increasing in number. By 20 days post infection, the spirochete resistant cells were seen uniformly throughout the flask.
Spirochetes also showed multiplication. The number of spirochetes increased. The spirochete resistant cells may provide some growth 2 0 factors for the multiplication of spirochetes.
After 12 days of culturing spirochetes in the cells, spirochetes were passaged in a new flask containing gut cells. In the first passage, the clumping of the cells was not seen until 4-5 days post infection. In this flask also, thespirochete ~tt~chmt-nt was seen only with small, round, clear cells. The large, round, 2 5 brown cells were not affected by spirochetes.
2. Amblyomma americanum These gut cells showed similar spirochete attachment. The only difference observed in this system was that clumping and attachment of spirochetes to cells was seen only after 4-5 days. The large, oval, brown cells were 3 0 not attacked by the spirochetes.
C. Anaplasma marginale This organism was obtained from peripheral blood collected from cattle suffering from anapl~cmosic or A. marginale-infected cattle in vacutainers containing heparin and which showed 27% par~citemi~3 as determined by blood smear 3 5 e~min~hon.
The buffy coat of A. mar~inale was removed by centrifugation and erythrocytes were washed 2x in L-lSB incomplete medium. The red blood cell ~VO 94/06463 21 ~ ~ 651 PCI/US93/08~
number was adjusted to 1.0 x 107 cells/mL in L-1~B complete meflium with all growth factors without antibiotics. Flasks containing approximately 5 mL of immortaliæd l~ermacentor andersoni and Amblvomma amencanum gut cells were inoculated with 1.0 x 106 celVmL infected erythrocytes (2 flasks for each cell type).
5 After inoculation, the cells were incubated at about 30C as described below.
Twenty-four hours post-inoculation of red blood cells (RBC~ into the culture, gut cells showed attachment of RBC onto the surface gut cells. This wasmore evident in Arnblyomma than the Derrnacentor cells (in both cell types theseattachments are seen). Forty-eight hours post-inoculation there was phagocytosis of 10 RBC by gut cells. The cell membrane of the gut cells became thick and numerous;
RBC were studded onto the surface of the gut cells. In addition, these gut cellsappeared dark brown.
Five days post-inoculation, the gut cells appeared highly granular, contained numerous minute uniform inclusion bodies, and many cells ruptured and 15 released these inclusion bodies into the surrounding medium. Culture samples were collected for tr~nsm;ssion electron microscopy for analysis of infected gut cells.
Changes were more evident in the Amblyomma cells.
Numerous modifications and variations of the present invention are included in the above-identified specification and are expected to be obvious to one 2 0 of skill in the art. Such modifications and alterations to the compositions and processes of the present invention are believed to be encompassed in the scope of the claims appended hereto.
Detailed Descl;u~ion of the Invention The present invention provides i~n~ alized tick cell lines and an 3 5 immortalized bovine T cell line. Such immortalized cell lines according to this invention are useful as, or in the production of, vaccinal agents, e.g., against ticks, and may provide protection against ~ise~es caused by pathogens, e.g., tick-bornepathogens.
WO 94/06463 2 1 ~ ~ 6 5 ~ PCr/US93/08~
As used herein, the term "i~ Ol L~lized cell line" refers to the cells depositedwith the ~m~ ~c~n Type Culture Collection (ATCC) as stated below. Immortalized cells of this invention may be clonally expanded by conventional techniques to produce a homogeneous population of progeny cell lines which can be m~int~ined 5 continuously in an appropriate culture m~ m Illlmol L~lized cultures of Dermacentor andersoni and Amblyomma amçricanum tick gut are provided. One example is the tick cell line called DGEC~This cell line, is describeA in detail and char~cteri7~d in Example 1. The line has remained stable for over 26 months and was deposited with the American Type Culture Collection (ATCC) on July 8, 1992 [ATCC Accession No. CRL 11084].
Also deposited with with ATCC on July 8, 1992 [ATCC Accession No. CRL 11083~, was the AGEC-1 imrnortalized tick cell line of the invention, which is discussedbelow in more detail.
Further, the invention provides an immortalized bovine T cell line, designated Bpbl-T1 (bovine peripheral blood lymphocyte-T cell). This immortalized bovine T
cell line is useful, inter alia, for T-cell dependent antigen targeting assays, T-cell receptor and antigen recognition studies, adoptive transfer experiments, and in vitro screening of cytokines, antigens and/or other bioresponse mo lifiers. This line has remained stable for over 8 months and was deposited with the ATCC on September 2 o l l , 1992 [ATCC Accessi~n No. CRL11120].
This invention further includes progeny and derivatives of these cell lines, e.g., cells which have been derived from the specific identified cell line by passaging or clonal expansion. All st~tements made herein relating to the il~ Ol L~lized cell lines of the invention are equally applicable to their progeny and derivatives.
2 5 Immortalized tick cell cultures of this invention are useful for, among other things, growing, in vitro, tick-borne pathogens, such as Borrelia burgdorferi. the causative agent of Lyme ~iice~ce~ and for producing antigens to these pathogens.These cell lines have also proven useful in m~int~ining vitro cultures of ~A.
marginale~ Fhrlichia species, and Borrelia bur~dorferi.
3 0 The immortalized T cells of the invention are also useful for growing a selected pathogen, as well as for producing antigens to these pathogens.
Additionally, the immortalized T cells of the invention are useful for the study of pathogens capable of infecting T cells, e.g. lentiviruses, and the study of T-cell signal transduction.
The i~ llulLalized cells of this invention provide a system for mass production of antigens, e.g., preferably cellular components such as proteins or non-proteinaceous material capable of inducing an immune response directed against a W O 94/06463 2 l ~ ~ G 5 1 PC~r/US93/08606 parasite borne pathogen. According to one embodiment, an immortalized cell of the invention may itself produce a biolog*al or therapeutic agent, e.g., a tick cellpolypeptide or protein, or another component or fraction of a tick cell which enh~nres the ability of a vaccine composition cnnt~ining a selected pathogenic 5 antigen to stim~ te a protective immune response in the vaccine. For exarnple, the o-lalized tick cell lines, AGEC-1 or DGEC-1, when cultured may naturally produce peptides, polypeptides, proteins, or other cellular fractions which are useful as anti-co~ nt~, anti-infl~mm~tnry agents and diuretics, for pharmaceutical and veterinary purposes. These exemplary and other agents are among the biological 10 products naturally produced by an imrnortalized cell of this invention upon culture.
Appropriate culture conditions to obtain maximum production of such natural products can be determined by one of skill in the art. These biological materials may be produced intr~cellnl~rly and obtained from the cultured tick cell by conventional cell disruption, e.g., lysis, and purification of the material or a cellular fraction 15 containing it from the lysate, based on its chPmiral identity or biological activity.
~ltrm~tively, the immortalized cell of the invention may secrete the agent into the media. Methods of isolating and purifying such biological materials or cell fractions are known in the art and may be utilized as desired.
According to another embodiment, the present invention provides a method 2 0 for producing antigens directed against a selected pathogen by infecting an imlllol Lalized cell culture of the invention with a selected pathogenic microorganism, e.g., ~3orrelia burgdorferi. Ehrlichia canis, Ana~ ma marginalis. Babesia bovis,Theileria parva. The infected iml.~ alized cell may, upon culturing permit the natural replication of the pathogen, and the production of pathogenic proteins in 2 5 culture. Either the pathogen itself, whether it be a virus or microorgani~m, or desirable proteinaceous m~trri~lc including subunits, polypeptides, cell fractions, fr~gmP,nt~ thereof, or other macromolecules such as carbohydrates, lipids, and lipoproteins may be produced in, and isolated from, the immortalized cell culture by conventional biological and genetic en ineering techniques. Such proteinaceous and 3 0 non-protein~reous materials, including the i~ lol ~lized cell or pathogen itself, are defined herein as antigens. Alternatively, the pathogens may be co-harvested from the cell culture infected by the pathogen.
It is understood that proteinaceous and non-proteinaceous materials produced by the pathogen-infected hlllllol ~lized cell lines may be include materials produced 35 from the immortalized cell biosynthetic activity. Pathogen-produced materialsisolated from the cell culture are expected to have use in vaccine compositions. For example, association of such pathogen-produced material with tick cell derived WO 94/06463 - `2 1 4 4 6 ~; 1 PCr/US93/0869 m~teri~l may provide vaccinal compositions with enhanced ability to stimnl~te immllnity in the vaccinee due to the influence of the tick cell environment upon the development and growth of the pathogen in the tick cell culture. In a similar manner, the illlll~Ul ~alized bovine cell line and products produced therein may be used to enhance vaccine compositions cont~ining bovine pathogens or antigenic materials t thereof. These cells and m~ten~l~ may further be of use in aiding identification of bovine antigens and in assaying for bovine cytokine production and activity.
Still an alternative embodiment for producing desirable antigens or polypeptides using an immortalized cell line of this invention involves transfecting the cell line with a recombinant molecule containing a heterologous polypeptide or protein having desirable antigenic properties under the control of a suitable regulatory sequence capable of directing the replication and expression thereof in the ihlllllolL~lized cell line. The transfected immortalized cell line containing the recombinant molecule is cultured to enable ~ ssion of the heterologous protein or polypeptide in the cell line. The methods employed in the design of the recombinant molecule, selection of the heterologous protein and regulatory sequences, and incorporation thereof into the cell line are within the skill of the art. [See, e.g., Maniatis et al., Molecular Cloning (A Laboratory M~mual), Cold Spring Harbor Press, Cold Spring Harbor New York (1989)].
2 0 Exemplary suitable vectors or plasmids for tr.msfecting the imlllol ~lized tick cells include those with an operational promotor, including insect viruses, insect recomhin~nt pl~mi(ls, Entomopox virus, and arboviruses. Currently, it is expected that insect promoters, such as polyhedron of baculovirus, spheroidin of entomopox virus, drosophila promoters or arbovirus (Semliki Forest Virus) would produce the 2 5 best results in the illllllOl Lalized tick cells. Similarly, vector components for m~mm~ n cells and known vectors may be readily selected by one of skill in the art for use in transfecting the bovine cell line Bpbl-Tl. See, for example, Maniatis et al, cited above.
The production of a desirable antigen from an immortalized tick cell line of 3 0 this invention is e~emrli~ l below (Example 3). Analogous procedures may beemployed to produce ~ntigens in the immortalized bovine cell line of the invention.
Media and cells from pathogen-infected illllllOl L~lized cells are generally collected at 24-108 hours post-infection and are used as the source of antigen for imm~lni7~tions.
If desirable, antigen-cont~ining media can be clarified from cell associated m~te~i~l by 3 5 centrifugation, aliquoted and stored at -20C until used. Alternatively, the pathogen ~ntigeniC m~teri~l may remain associated with any cell material from the imrnortalized cell and be incorporated into a vaccine. Immortalized tick cell produced material in ~094/06463 21~t651 PCI/US93/08606 association with the seleGte~l pathogen antigen may enhance the immunostim~ tQryeffect of the pathogen antigen. All antigen preparations can be quantified for parasite-specific protein (PSP) with ELISA. Cell-associated antigen may be prepared by sonication on ice in serum-free media followed by the centrifugation step 5 described above. Protein concentrations are determined by the method of Bradford, Anal. Biochem.~ ~:248 (1976). Sonicated parasite suspensions are adjusted to a final concentration of 10-100 ~lg/mL in serum-free media, aliquoted, and stored at -20C
until use.
The pathogens may express receptors on the cell surface of the illllllOl L~lized10 cell of the invention or intracellularly. Alternatively, the pathogens are contained intr~cell~ rly and released when the immortalized cell is disrupted in vitro or is processed in vivo by the animal vaccinated with the pathogen-containing immortalized cell. Disruption may be accomplished using known means, e.g. by freeze-thawing or other biochemical or mechanical disruption. In still another 15 alternative, antigenic portions of the pathogen are purified or left in combin~tion~ i.e.
the antigens may comprise a mixture of unpurified cellular material, viral subunits or fr~gmentc, media, and, optionally an adjuvant, from the imlllol~lized cell in which they are produced and used in a vaccine formulation.
The antigens produced as described above can be employed in the preparation 2 0 of a vaccine. The vaccine comprises an immunogenic amount of one or more antigen produced by the invention in a form suitable for internal ~(iministration.
Such a vaccine, directed against the selected pathogen or parasite, comprises an immunogenic amount of at least one pathogenic antigen which is produced by growing an immortalized cell culture of this invention infected with the selected 2 5 pathogen, including viruses and microorganicmc. The pathogenic antigen, as defined above, includes the entire pathogen, desirable subunits, polypeptides, cell fractions or fr~gmentc thereof, or desirable non-proteinaceous material.
Alternatively, the vaccine contains a whole in mortalized cell and the pathogen antigen. The pathogenic a~ntigen may be expressed in the i~ alized cell3 0 intracellularly, on the cell surface, or secreted during the natural processing of the cell or a vaccine fc)rmlll~tion containing a pathogen-infected hlllllollalized cell by the host. ~ltern~tively, such a vaccine composition may contain some cellular component of the immortalized cell which is not the whole cell, e.g., an irnmunogenic protein or polypeptide fragment of the immortalized cell, a subunit non-proteinaceous 3 5 material, or mixtures thereof.
In another embodiment, a vaccine is designed to protect against a tick. Such a vaccine composition contains an immunogenic amount of an immortalized tick cell _, 7, -- 6 5 1 of the invention, a cellular fraction, an antigenic protein or fragment of the cell, or other suitable immllnogenic fragments of an i~ o~lized cell of the invention. Inanother embodiment, the anti-parasite vaccine of the invention may contain both of the immortalized tick cell lines of the invention, or combinations thereof, whether as 5 whole cells, cellular fractions, or only proteinaceous or desirable non-proteinaceous materials from the cells. Further, these vaccine compositions may include other conventional anti-parasitic agents suitable for internal ~lmini~tration and/or be ~-lmini~tered in connection with other, known tick vaccinal compositions. Example 2 illustrates cross-species reactivity with an anti-tick vaccine of the invention.The AGEC-1 and DGEC-l immortalized tick cell lines of the present invention and the Bpbl-T1 bovine cell line are used to prepare vaccines with or without incorporated and replicating pathogens (See Example 3) and a pharmaceutically acceptable carrier. For example, as a tick vaccine, the uninfected or non-pathogen associated tick cells are replicated to the desired volume and cell15 density using large scale cell culture procedures known to those in the art such as (e.g., roller bottles, microcarrier, suspension, hollow fiber, etc.). The cells are harvested by standard procedures and concentrated by ultrafiltration or centrifugation. The cells are inactivated by 1-3 cycles of freeze-thaw, or heat or suitable chemical inactivation. The inactivated cells are then adjuvanted under 2 0 optimal conditions to provide a suspension of cells and adjuvant. The bovine cells may be analogously manipulated for the preparation of a vaccine composition.
In another formulation, the membrane proteins of the immortalized cells harvested can be fractionated by standard methods to form a vaccine containing only a part of the immortalized cell of the invention alone or in combination with other 2 5 antigens. This vaccine would not need an inactivation step, but may optionally be adjuvanted and arlminictçred in the manner described above. Similarly, one of skill in the art can identify desirable immunogenic proteins, peptides, or polypeptides derived from an i~ lized cell of the invention for inclusion in a vaccine composition ofthe invention. Such proteins, peptides, or polypeptides once iclentifie A can be3 0 isolated and purified, produced recombin~ntly, or synthesized by known means.
Vaccines of this invention may be employed in a method of immnni7ing hum~ns or anim~ls against a selected pathogen by injecting a vaccine of this invention into the animal.
As one example, a vaccine composition may contain as one of its active 3 5 ingredients a selected Borrelia antigen produced in cell line AGEC- 1 or DGEC-1, and either purified from the cell line or used in association with cellular material from the tick cell line. Such a vaccine is desirably ~mini~tered to humans and animals to ~O 94/06463 2 1 4 4 6 5 1 PCI/US93/08606 stim~ te ill " "llllily against Lyme disease or ticks. Where the vaccine comprises Borrelia antigens only, the vaccinee may develop ;"",~,.;ly against the spirochete, the causative agent of Lyme ~lice~e Where the vaccine also contains tick cell antigenic m~t~ri~l, the vaccinee may develop an immune response which destroys the tick - 5 before it can transfer the spirochete to the vaccinee. In the same manner, a vaccine of this invention can be used to protect against Rocky Mountain spotted fever, Ehrlichiosis, arboviruses, anaplasmosis, theileriosis, babesiosis, cutaneous irritations, and allergic dermatitis, where the antigen produced in the cell line is derived from one of the pathogens causing that condition.
~ltern~tively, where a vaccine of the invention is form~ te-l to be protective against Lyme tli~e~e, the whole immortalized tick cell, or a cellular fraction or subunit, a tick cell protein or peptide fragm~nt, or combin~tion thereof, from the immortalized cells may provide one vaccine component to stim--l~te immllnity to the tick cell. A tick cell vaccine component may be separately ~rlmini~tered with a vaccine containing a whole, inactivated pathogenic cell or subunit vaccine prepared from Borrelia. In other words, the Borrelia antigen does not have to be produced in the immortalized cells. It may be produced in another conventional way and co-~rlminictered with an immortalized tick cell component-containing composition.
Alternatively, in the present invention, Borrelia are grown in the immortalized cells 2 0 and then the entire il~ ol ~lized cells and spirochete material are harvested, inactivated, and preferably adjuvanted as described above. Another embodiment involves se~ting the spirochete or spirochete-produced proteins or antigenic fragments from the immortalized cells after growth and preparing the spirochetes or proteinaceous fr~gm~nts separately from the cells as a vaccine. In this case, the 2 5 spirochete is inactivated, or a protein isolated and adjuvanted in a similar manner.
Thus, the present invention provides a vaccine useful in preventing infection with any tick-borne pathogen. Such a vaccine composition contains an immortalized tick cell of the invention, or an immunogenic or antigenic fragment thereof, and an antigen directed to the selected pathogen. This antigen may be a whole inactivated 3 0 viral or cellular pathogen, or an antigenic protein, macromolecule or polypeptide thereof. For example, in a preferred embodiment, an anti-Lyme disease vaccine contains both the immortalized cells and any Borrelia bur~doferi antigen. An example of such an antigen is the spirochete, described in Example 9. However, this invention is not limited to an antigen produced in association with the illllllOI lalized 3 5 tick cells of the invention, but the Borrelia antigen may be obtained from other sources. It is anticipated that such a vaccine would offer superior protection over a vaccine containing solely the spirochete or subunits thereof.
WO 94/06463 2 1 ~ 4 6 5 1 PCI/US93/0861~
~. .
An immortalized cell of the invention can also be used as a recombinant vector for expression of a gene from a selected pathogen, e.g., Borrelia. Thus the need for growing and m~int~ining the spirochete would be elimin~t~rl Such a recombinant veetor expressing the gene for Borrelia is introduced into the immortalized tick cells. The tick cells e~lt;s~.ing the gene are harvested as described above, inaetivated, adjuvanted, and optimiæd for stability and efficaey.
For example, certain Borrelia express outer surface proteins (OSPs) which are capable of dir~elllially distinguishing between Borrelia grown in standard laboratory media and Borrelia passaged through live ticks. Using a recombinant DNA
approach, genes representing the OSPs from Borrelia vectored by live ticks could be isolated and expressed in an ap~ iate vector. Particularly useful vectors include the Semliki forest virus vector, the baeulovirus vector and the entomopox virus vector. The ill~lllulL~lized tick cells of the invention, infected with these viruses to produce the desired antigen are processed as whole cell or subunit extracts as described above.
Typically, antigenic proteins produced in association with the imrnortalized cells of this invention are desirably employed in vaccine compositions. For example, an immunogenic amount of an antigenic protein or desirable non-proteinaceous material are mixed with a ph~Tm~eutically acceptable carrier. An immunogenic 2 0 amount of a selected pathogenic antigen is generally between about 0.01 llg to 10.0 mg antigen, more preferably 0.05 ~Lg - 1 mg, and may be determined by one of skill in the art depending on the identify of the antigen, pathogen, and host animal.
An imm~lnogenic amount of the illlmollalized tick cells is about 101 to 108, and preferably about 106 cells/dose. Alternatively, the total immortalized cell 2 5 proteinaceous material, cellular fractions, or desirable non-proteinaceous macromolecules is in the range of 0.05 llg to 1 mg, as described above for the pathogenic antigens above. However, one of skill in the art ean make appl.,pliate adj~lstm~t~ depending upon the vaecine.
In adrlitiQn to the aetive ingredients discussed in the preeeding paragraphs, 3 0 other optional ingredients inelll-ling, for example, stabilizers, e~riers, and adjuvants may be added to the vaccine compositions of the invention. Stabilizers are addedoptionally to provide longer shelf life or enhance the poteney of the forrn~ tedvaecines of the invention. Typieally, stabiliærs, adjuvants, and inaetivation agents are Optil~ ed to determine the best form~ tion for efficacy in the target animal.
3 5 Suitable stabilizers, as with the other op~ional ingredients, are well known to those of skill in the art. Examples of such st~bili7ers inelude e~c~mino acids, sucrose, gelatin, phenol red, N-Z amine AS, monopotassium glllt~m~te, potassium ~0 94/06463 PCI/US93/08606 ~1~4651 monophosphate, potassium diphosphate, bovine albumin fraction V, lactose, lactalburnin hydrolysate, dried milk, and heat inactivated serum.
Suitable ph~rm~ceutically acceptable carriers facilitate ~tlmini~tration of the proteins and antigens but are E3hysiologically inert and/or nonharmful. Carriers may 5 be selected by one of skill in the art. Exemplary carriers include sterile saline, lactose, sucrose, calcium phosphate, gelatin, dextrin, agar, pectin, peanut oil, olive oil, sesame oil, and water. Additionally, the carrier or diluent includes a time delay material, such as glyceryl monostearate or glyceryl distearate alone or with a wax. In addition, slow release polymer formulations can be used.
The vaccine compositions of this invention may be incorporated into convention~l sustained-release matrices, implant formulations, tablet formulations or injectable sustained release formulations and matrices. Components of such formulations are well known to the art.
One or more of the above described vaccine components may be admixed or adsorbed with a conventional adjuvant. The adjuvant is used as a non-specific irritant to attract leukocytes or enhance an immllne response. Such adjuvants include, among others, mineral oil and water, aluminum hydroxide, Amphigen, Avridine, L121/squalene, D-lactide-polylactide/glycoside, pluronic polyols, muramyl dipeptide, killed Bordetella. saponins, saponin-derivatives such as Quil A, and Immune 2 0 Stimul~tory Complexes (ISCOMs).
Inactivation agents may also be included in the vaccine formulations of the invention. Suitable inactivation agents include formalin, glutaraldehyde, binaryethylçneimine (BEI), beta-propriolactone, and heat, and freeze/thaw techniques. Other suitable agents are well known in the art.
A desirable dosage of a vaccine of the invention involves the ~lministration of 1 to 3 doses of desired vaccine composition, where the desired antigenic content of each fraction is as stated herein. The vaccine is preferably ~tlmini.ctered in two injections intramuscularly or subcutaneously, approximately 2 weeks to 3 months apart to immllni7e and boost the immune system of the target animal. However, the 3 0 mode of ~ministration of the vaccines of the invention may be any suitable route, including intradermally, intravenously, intraperitoneally, transdermally, topologically (e.g. by patch ointment) and by implant.
The specific dose level, mode and timing of aflmini~tration for any particular animal depends upon a variety of factors including the age, general health and diet of 3 5 . the animal; the species of the animal; and the degree of protection being sought. Of course, the ~lmini~tration can be repeated at suitable intervals, such as annually, if necessary or desirable.
21~6~:~
W O 94/06463 `~ PC~r/US93/086 For example, in cattle, the volume of the dose may vary from 0.1 to ~ mL of a sterile preparation of an immunogenic amount of the active vaccine component or co~ onents to 0.1 to 1 mL in a small animal such as a dog or cat. The immnne measurements to detect active immnni7~tion of the t~rget animal can be determined 5 by testing titers of antibody to cell protein using vitro detection systems such as ELISA.
In another aspect, the immortalized cells of the invention may provide si~ni~lc~nt thel~peuLic products. The ap~ liate me~linm and other conditions under which to culture an illlll~l L~lized cell line of this invention to enable it to produce a 10 desired therapeutic agent can be readily determined by one of skill in the art by conventional techniques. Such a therapeutic agent may be secreted directly into the culture medium and isolated by conventional techniques by one of skill in the art.
~ltern~tively, if expressed internally, the agent can be isolated from a culture lysate of such cells using known techniques.
Thus, the present invention also provides a method of immllni7ing animals against tick infest~tion, Lyme rlise~e, and other tick-borne diseases by ~lmini~tering to an animal a vaccine compostion of the invention. For the method of hl,mu"izing ~nim~l~ against tick infestation, the vaccine composition of the invention contains an immunogenic amount immortalizing tick cell of the invention, DGEC- l, AGEC- l, 2 0 progeny or derivatives thereof, or combinations of these cells. For the method of ir~ ing animals against Lyme disease, the vaccine composition of the invention may contain an immunogenic amount of one or more B. bur~dorferi antigen produced in, on, or by an illllllc,llalized tick cell line of the invention, an immortalized tick cell line of the invention alone or in combination with one or more ~3. burgdorferi antigens, or a combin~riQn of these.For the method of immnni7ing ~nim~ls against a selecte~l tick-bome ~lise~e, the vaccine composition of the invention may contain an immnnogeniC amount of one or more antigen from the pathogen which causes the tick-bome disease produced in, on, or by an illmlol~alized tick cell line of theinvention, an immortalized tick cell line of the invention alone or in combination with 3 0 one or more of the pathogen, or a combination of these.
The present invention further provides a method of immuni7ing animals against a selected pathogen, where said pathogen is capable of being grown in association with the immortalized bovine T cells of the invention. In par~cular,bovine lellk~mi~ virus, bovine immunQdeficiency virus or other pathogens which 3 5 infect bovine lymophocytes are anticipated to be suitable pathogens for growth in the c Bpbl-Tl i~llmol~lized bovine T cells:
~ro 94/06463 2 1 ~ 4 6 5 I PCr/US93/08606 The imrnortalized cells of the invention also provide a source of diagnostic reagents. For example, the DGEC-1 or AGEC-1 i~ ol~lized tick cell lines of the invention, or preferably protein sequences thelc;Lulll, may be used as diagnostic reagents in an in vitro assay to detect the presence of a pathogen, particularly a tick-borne pathogen, in a sample of body fluids from an animal suspected of infection. In addition, pathogens produced in the immortalized cells of the invention, and their protein sequences may also provide diagnostic agents for the pathogen. Further, the specificity of the illllllOl ~alized cell receptors can be used to determine typing of org~nicmc isolated from patients suspected to have been exposed to such org~nicms.
1 0 Once the ,cce~ is identified, receptor specific typing can be performed.
Such a diagnostic assay preferably involves the association of the cell line of the invention with a detectable label and the incubation of this diagnostic reagent with the sample fluids. For example, the specificity of the receptors on the immortalized tick cell sof the invention, can be used to type org~nicmc isolated from patients suspected of being bitten by a tick. Because the DGEC- 1 cell specifically agglutinates strain 297 of Borrelia burgdorferi~ agglutination could be used to type other B. burgdorferi strains. Binding of a pathogen to the cells can be detected by a variety of conventional assays, including agglutination, amplification, stim-llRtion of a pathogen antigen, e.g., OSP on Borrelia, and competition binding lltili7ing a MAb to 2 0 the pathogen, e.g., Borrelia, or a receptor on an immortalized cell line of the invention.
In one embodiment, B. bur~dorferi specifically agglutinates after attachment to DGEC-1 cells in vitro, intlic~ting a specific receptor on tne B. burgdorferi and DGEC-1 cells. After several days of attachment, the B. burgdorferi are inducecl to 2 5 replicate. Normally, B. burgdorferi will not replicate in DGEC- 1 media. The binding, ag~lutin~tion and det~chm~nt denotes an activation (synergy) step between B. bur~dorferi and DGEC- 1. Thus, the immortalized cells and/or B. burgdorferi may elaborate growth factors in the media.
Antibodies to a receptor(s) on the il~l,lol~lized tick cell lines of the invention, 3 0 DGEC- 1 or AGEC- 1, may be used in diagnostic assays. Conventional techniques for making suitable polyclonal, recombinant, or more desirably, monoclonal antibodies are well known to those of skill in the art [see, e.g., Kohler and Milstein; W. D. Huse et al., Science. ~ 1275-1281 (1988); PCT Patent Publication No.
PCT/W086/01533, published March 13, 1986; British Patent Application No.
GB2188638A, published October 7, 1987; Amit et ~1-, Science~ ~:747-753 (1986);
Queen et al., Proc. Natl. Acad. Sci. USA~ ~:10029-10033 (1989); PCT Patent Publication No~ PCT/WO90/07861, pubiished July 26, 1990; and Riechmann et al., 21~551 WO 94/06463 ; ~ ; PCr/US93/08 ~ature, ;~:323-327 (1988)]. For ~ gnostic purposes, the antibodies may be associated with individual labels, which are preferably interactive to produce adetectable signal. Most preferably, the signal is visually detectable. For colorimetric detection, a variety of enzyme systems have been described in the art which will5 operate ap~lop~;ately.
Antibodies specific for receptors on DGEC-l or AGEC-1 may also be used therapeutically as targeting agents to deliver therapeutic compounds. Rather than being associated with a label, such a therapeutic agent employs the antibody linked to an agent or ligand capable of disabling the replicating mechanism of the pathogen.
10 Alternatively, the antibody may block binding of the pathogen to the target cell.
Such antibodies may also be useful in therapeutic compositions for treating tickinfestations.
The following examples are merely illustrative of the different aspects of this invention and are not intended to limit the scope of the present invention.
F.xample 1 - Characterization of Transforrned Cell Line The im~lloll~lized cells DGEC-1 derived from the intestinal epithelial tract of Dermacentor andersoni show continuous growth and replication by a budding process, which can result in "chain-like" clusters of cells. Growth characteristics 2 0 change with increased duration in culture. However, replication rates among gut cells transformed according to this method vary, as does the ease of transformation.
At approximately nine months after initiation of cultures, the cell replication rate increased and slight morphological changes occurred. A distinct nucleus became visible for the first time. It is possible that cells required this time to accommodate to 2 5 culture conditions and to delete transfected DNA, which is not needed for cellular growth and development.
Three types of cells have been observed in the heterogeneous population:
small, round and clear; large, granular and brown; and large clear cells. Cells possess phagocytic activity throughout the culture period. ~ntimif~robials have been removed 3 0 from est~bliche~l cultures without any detectable changes in cellular growth characteristics.
The DGEC-l cell line was further characterized by (1) selective ~tt:~chment by Borrelia burgdorferi (receptor metli~tor), (2) differential phagocytosis of red blood cells in mixed blood cell populations and (3) induction of immnne response in guinea 3 5 pigs that reduced tick infestation and feeding. The line has remained stable for over 15 monthc.
~ro 94/06463 2 1 g 4 6 5 1 PCr/US93/08606 Further, this cell line, as well as illll~lUl ~lized intestinal epithelial cellsfrom ,~mblyomma ~rnericanum (AGEC-1), have proven useful in maintaining in vitrocultures of A. n~ ale. ~, bur~dorferi. and F~hrlichia species. It is expected that these cell lines will also be useful in maintaining in ViVO cultures of Arboviruses, 5 Babesia, and other tick-borne pathogens.
The growth of certain of these pathogens is demonstrated in Example 3 below.
Exarnple 2 - Immunization of Guinea Pi~s with Il--n~ol lalized Tick Gut cells Successful vaccination of guinea pigs with tick gut extracts is always accompanied with a specific antibody titer than can be enhanced upon repeat vaccinations. These antibody titers are normally measured by ELISA tests. To determine whether the immortalized gut cells have retained the ability to synthesize important antigens for immunological control of ticks, the cells were used to vaccinate guinea pigs. Three ~al~lllcters are used to ~letermin~ whether the guinea pig has been successfully immllni7eA against tick infestation: (a) death during or shortly after the blood meal is taken, (b) reduction or elimin~tion of ovipositing (egg laying), (c) reduction or lack of hatching from egg mass that is laid. These parameters are additive in the clinical measurements against tick infestation since any 2 0 can block the tick life cycle. This example describes the results of vaccination and challenge studies in the guinea pig model and demonstrates production of antibody against the immortalized tick cells that cross react with native tick gut tissue in an ELISA format.
The continuously growing tick gut cells of the invention were harvested from L-15B complete medium, centrifuged (at 150 x g; 10 minutes), and washed 3x in L-l5B incomplete ..,~li-.... The cells were then resuspended in L-15B incomplete medium and adjusted to 1.0 x 106 cells/mL. One million cells were a~lmini~t~red by subcutaneous injection to each guinea pig on days 0 and 14. Each injection was in a volume of 1 mL, and given in a dose divided between two sites. A total of 12 guinea 3 û pigs: 6 for Amblyomma americanum cells and 6 for Dennacentor andersoni cells were used. Two weeks after the last injection of cells, the ~nim~l~ were bled bycardiac puncture, 4 mL of blood from each animal was collected, serum separated and stored at -20C. Tmmllni7ed ~nim~l~ developed strong antibody responses as determined by enzyme linked immunosorbent assay (ELISA) as described below.
3 5 The antigen was prepared as follows. Adult, female, unfed DelTnacentorandersoni and Amblyomma americanum (200 each) were surface sterilized and their gut tissue was collected in sterile PBS (pH 7.2, 0.15 M). The gut preparation was W0 94/06463 2 t ~ Bsl PCl/US93/08 sonic~te~ and the protein content det~rmined by bicinchoninic (BCA) assay as described in P. K. Smith et al, Analytical Biochernistry. 150:76-85 (1985).
The coating for the wells was made up of 5 ~lg/mL of gut antigen suspended in carbonate-bicarbonate buffer, loaded 100 ~Vwell, and incubated at 4C overnight.
5 The wells were blocked with 1 % bovine serum albumin.
Serum dilutions (both control and immune) were made from 1:10 to 1:20480.
The second antibody used was rabbit anti-guinea pig (IgG, H&L) in HRPO, 1: 1000 in 1% BSA (PBS, 0.05% Tween-20). The substrate was o-phenylene dramine [OPD;
Eastman Kodak, Rochester, NY] and the optical density was read at 490 nm. The 1 0 results of these assays are set out in Tables 1-3 below.
Tables 1 and 2 set out the results of an assay performed on guinea pigs immllni7ed with Amblyomma americanum gut cells ill-l,lol~alized by the techniquedescribed in Example 5 above. The native gut antigen (5 ~Lg/mL) was 500 ng/well in 100 ~LL-as determine~ by enzyme-linked immunosorbent assay, ELISA, using known 1 5 techniques. Tick gut protein concentrations were deterrnined prior to testing as a standard. Each well was coated i~le~tir~lly, each using the same antibody dilution and detector antibody. Labelled antibody was rabbit anti-guinea pig-HRPO (IgG, H&L), 1:1000. The pre-imml-ni~tion titers (OD160) of A. americanum antigen were 0.037 and of D. andersoni antigen were 0.064.
2 0 Table 1 represents the detennin~hon of antibody response in anim~ls imml-ni7P~l with irnmortalized A. americanum cells (AGEC-1) and not challenged with ticks. The time periods indicate the time after inoculation at which the sera was tested. The antigen refers to the antigen used in the test.
2 5 Table 1 FIVE WEEK POST-INJ. S~X WEEK POST-INJ.
NATIVE GUT ANTIGEN NATI~E GUT ANTIGEN
Guinea Pi~ Amblyomma l:)ermacentor Amblyomma Dçrmaçentor 1009 1.313 1.187 1.267 1.306 1010 1.144 1.036 1.230 1.292 1011 0.687 0.785 1.064 1.047 The following data represents the deterrnination of antibody response by ELISA in animals immnni7ecl with immortaliæd A. americanum cells and which were 3 0 tick challenged.
~Vo 94/06463 2 1 4 4 S ~ii 1 PCr/US93/08606 Table 2 NATIVE GUT ANTIGEN
Guinea Pi~ Amblyomma Dermacentor 1018 0.326 0.340 1019 0.545 0.667 1020 0.459 0.711 1021 0.381 0.203 1022 0.303 0.429 1023 0.461 0.613 Single cell suspensions were prepared from D. andersoni freshly isolated gut.
5 The isolated cells were frozen and thawed. Guinea pigs were imm~ni7e~l with this preparation at 0.5 mg per mL per animal. A total of three booster injections were given with a 10 day interval between inoculations. As can be seen from the data in Table 3 below, ~nim~l~ immllni7ed with the immortalized ~ermacentor andersoni gut cells (DGEC-l) developed strong antibody responses. The antigen of Table 3 is that 1 0 used for screening.
Table 3 NATIVE GUT ANTIGEN
Guinea Pi~ Arnblyomma l:~ermacentor 1024 0.167 0.343 1025 0.208 0.334 1026 - 0.160 0.442 1027 0.617 0.947 1028 0.495 0.458 1029 0.485 0.468 1 5 The antibodies generated against freshly prepared tick gut tissue by imm-lni7~tion of guinea pigs were used in immllnofluorescence assays to detect reactive epitopes on immortalized tick gut cells m~int~ine~l in culture for 11 months.
These guinea pig antibodies were obtained from animals that were subsequently challenged with ticks. After collection of sera for immunoloc~l;7~tion, immnni7e~
2 0 anim~lc were challenged with larvae, nymphs or adults of the sen~iti7ing species.
This immunolocalization data correlates with the protective study results.
WO 94/06463 2 1 4 ~ ~'1 PCI/US93/086~
Table 4 below illustrates the effect on the life cycle patterns of Dermacentor andersoni ticks on control ~nim~l~ and may be con.~a,ed with Table S which illustrates similar data on animals immllni7~d with Dermacentor andersoni native gut antigen.
Table 4 ~infest/ Feeding Physical *replete davs Wei~ht Dead/live Appearance Larvae 280/275 4 5/275 Hatched Nymphs 60/60 6 0/60 Molted Adults 8/8 8-10 946 mgs* 0/8 1034 mgs*
1023 mgs*
943 mgs*
1045 mgs*
988 mgs*
1038 mgs*
1011 mgs*
Table 5 ~infestl Feeding Dead/ Physical ~replete davs Wei~ht live Appearance Larvae 230/216 4 14/216 Adults 8/4 18-19 392 mgs 4/4 435 mgs 643 mgs 572 mgs This data shows that animals ;,.",~ni,ed with freshly prepared D. andersoni gut cells were resistant to infestation with adult ticks. None of the four female ixodids allowed to infest ;.~ i7efl guinea pigs produced ova, inrlicating a clear anti-1 5 tick response.
Tables 6 and 7 below illustrate this effect on Amblyomma americanum and Dermacentor andersoni ticks in animals immllni7Pd with Amblyomma americanum gut cells immortalized by the technique described above.
~VO 94/06463 2 1 ~4 6 51~ PCl/US93/08606 Table 6 - ~. americanum ticks #infes~/ Feeding Dead/ Physical #replete davs ~k'E~ li~ A~pearance Larvae 220/253 4 228 mg/0.9 mg nl Molted Nymphs 60/4~ 6 572 mg/12.71 mg n' Molted 1019 (75.0%) Adults 1020 8/8 12 23 mg 12 434 mg Dead Reddish 13 690 mg Reddish 14 55 mg Dark red 19 35.6 mg Dead Dark red 19 34.8 mg Dead Dark red 19 15.6 mg Dead Dark red (100 % dead) n1 (100% fed larvae survived) n2 {45 Molted to adults (7S.0%), 15 dead (25.0%)}
The red color indicates that the tick guts apparently rlicintegrated. One tick burst in capsule. The adult ticks in this study either died or were incapable of laying eggs. None produced egg mass.
WO 94/06463 2 1 ~ 4 6 5 1 PCI/US93/089 rable 7 - D. andersoni ticks #infest/ Feeaing Dead/ Physical #re~lete davs Weight ~ A~earance Larvae Nymphs 60/52 8 1421 mg/27.33 mg 23/29 29 grey 1022 (86.7%) nl 23 black Adults ~Eick) (E~ Mass) 1023 8/8 12 485 mg 244.9 mg* Dark red 12 792 mg 523.0 mg Grey 12 579 mg 358.6 mg* Grey 13 786 mg 465.8 mg Grey 13 539 mg 235.9 mg Grey 13 405 mg 198.9 mg Grey 14 498 mg 323.6 mg Grey 250 mg Grey nl { 17 molted to adult (28.3%), 43 dead t81.8%)) 5 * For the adults, in~licates that the ova produced by females did not hatch.
The lack of data for larvae inclic~tes that they did not attach to the host.
However, while there was no feeding, a severe cutaneous reaction was seen at thebite site. No egg mass was produced for those feeding 15 days. The data further 10 in~1ic~tes that the i~ i7~tion induced cross-species protection which is indicated by longer times to replete, lower finished weight and reduced viable egg mass.
Tables 8 and 9 below illustrate this effect on Amblyomma americanum and Dermacentor andersoni ticks in animals il~ lul-i~;d with il....lol~lized Dermacentor andersoni gut cells obtained by the technique described above.
~0 94/06463 PCI/US93/08606 Table 8 - 1~). andersonl t~
#infest/ Feeding Dead/ Physical #rçplete davs Weight live Appearance Larvae:
Nymphs:
1025 60/38 8 1058 mg/27.84 mg nl 31 grey (63.3%) 7 black Adults:
1026 8/6 12 768 mg dead black 12 972 mg dead dark red 12 791 mg* grey 12 936 mg** grey 13 970 mg dead reddish 19 15.6 mg grey nl {25 molted to adults (41.7%), 35 dead (58.4%)}
5 * Tn-lic~tes the production of egg mass (324.6 mg), which did not hatch.
** Tn~ ates the production of 353.5 mg egg mass.
Two ticks died early during feeding period. The lack of data for larvae indicates that there was no attachment. However, while no feeding occurred for 1 0 larvae, a severe cutaneous reaction was seen at the bite site.
_ WO 94/06463 2 1 4 ~ 6 S 1 PCI/US93/08~
Table 9 - A. americanum ticks ~infest/ Feeding Dead/ Physical ~replete ~ Weight 1~ Ap~earance Larvae 200/210 4 174 mg/0.83 mg Molted Nymphs 1028 60/38 6 366 mg/9.63 mg all grey {37 molted to adults (61.7%), 23 dead (38.4%)}
Adults 1029 8+8 14 296 mg dark red 14 370 mg* grey 14 417 mg** grey 276 mg dead black 18 158 mg dk grey 18 315 mg dk grey 19 37.5 mg grey 19 23.4 mg dead black * Indicates production of 131.5 mg egg mass.
5 ~* Tnclic~tes the production of 167.4 mg egg mass.
Anirnals immnni7e~ with immortalized cells were challenged with larvae, nymphs or adults of the homologous species. Prelimin~ry observations indicated that resistance to adult and nymphal challenge was present. Adult ticks required longer to 0 feed and engol~,e~ t was altered. Many male, female and nymphal ticks died after engorgement. In addition, production of ova was reduced. Immortalized digestive tract cells of ~. americanum appear to srimlll~te a more solid resistance to infestation than cells of D. andersoni origin.
This data indicates that the immun;7~tion induced some cross-species 1 5 protection.
Exam~le 3 - Growing Patho~ens in Immortalized Tick Cells A. Ehrlichia canis and Granulocytic Canine Ehrlichia Both Ehrlichia canis and Granulocvtic canine Ehrlichia (GCE) have been successfully grown in the illlll~ol~alized gut cells of Derrnacentor andçrsoni 2 0 (DGEC- 1} and Arnblyomrna arnericanum (AGEC- 1). The Ehrlichia was obtained from peripheral blood collected from dogs which were exp~rimellt~lly infected with these or~ni~m~. ~ canis is associated with lymphocytes and monocytes. GCE is associated with granulocytes. The peripheral blood was collected in vacutainers .
cont~lnlng hepann.
~O 94/06463 2 1 4 4 6 5 1 PCr/US93/08606 Peripheral blood lymphocytes (PBL) were isolated by Ficoll gradient (Histopaque) and washed 3x in L-lSB incomplete me~ m The cell numbers were then adjusted to 1.0 x 106 cells/mL and added to a flask containing gut cells (6 mL) (a few erythrocytes also were present in the peripheral blood lymphocyte 5 preparations.
Granulocytes were isolated from blood by the method described by Sigma Chemic~l~ using Histopaque 1077 and 1119 in a double gradient method.
Isolated granulocytes were washed 2x in L-15B incomplete medium inoculated to gut cells (1.0 x 106 cells/mL).
1 0 Microscopic ex~min~tion of cultures 2-3 days post infection showed aggregation of PBL/granulocytes around the gut cells. This was very evident in Amblyornma americanum gut cells, since they are big, oval and larger than PBLs/granulocytes. About 2-3 weeks post-inoculation, the cont~min~tecl RBC
degenerated, PBL/granulocytes showed rough surfaces and numerous granular 1 5 m~t~ri~l was observed in cultures. In addition, Amblyomma cells showed phagocytosis of hemoglobin (appeared red in color).
Eight to ten weeks after infecting cells, the minute bodies increased in number and many of these bodies studded on to the surface of the gut cells, particularly on Amb~yomma americanum gut cells. Diff-Quick stained culture smears 2 0 and one micron thin sections (toluidine blue stained) showed numerous bodies (lawn of uniform bodies), which were also studded on the surface of the gut cells.
Serum samples collected from dogs suffering from Ehrlichiosis were used as a source of antibody and used to identify the or~"ni~m~ in cultures by Florescent Antibody Test. Acetone fixed smears of culture were reacted with 2 5 antibodies to Erhlichia. and these immunoglobulins were localized by fluoroscein isothyocyante (FITC) conjugated anti-canine antibodies.
Cultures with material from infected dogs displayed reactivity. Immortalized gut cells had the appearance of being studded with minute fluorescent bodies.
B. P~orrelia bur~dorferi 3 0 Borrelia bur~dorferi strain 297 [SmithKline Beecham Animal Health]was grown in conventional BSK-II medium according to known techniques. Strains B31 [SmithKline Beecham] and SH-2-82 [National Institutes of Health] of B.
r burgdorferi have also been established. Two vector competent strains include 27985, isolated from I. d~~ filli in Stamford, Connecticut, and 21305, which was isolat ed from Peromysus leuco~us [both of which are available from John Anderson, Connecticut Agricultural Resource Station~. However, other, known, strains of B.burgdorferi may be used.
WO 94/06463 2 1 ~ 4 6 5 1 PCr/US93/08~
An 8-10 day old culture of B. burgdorferi strain 297 (200 ~L) was added to each of two T-25 flasks. Dermacentor andersoni irllllwl L~lized gut cells (DGEC-1) and Arnblyomma americanum immortalized gut cells (AGEC-l) were cultured in antibiotic-free L-lSB complete m~illm 24-48 hours prior to inoculating 5 with the spirochetes. The spirochete infected tick cell cultures were incubated at 30 C in a dry incubator as described below.
1. Dermacentor andersoni The spirochetes started attaching to the cells by 24 hours post infection. As the incubation continlle(1, the clumping of cells by spirochetes 10 increased. By 4-5 days post infection, clear entanglement of cells by spirochetes was evident. It was observed that the cell types in the culture, small, round, clear gut cells were att~cked by the spirochetes. The large, round, brown color cells may be resistant to spirochete attachment. By 10-12 days post infection, the spirochetesensitive cells were disintegrated and only spirochete resistant cells were present in 15 the culture. By 15 days post infection, the so-called spirochete resistant cells started multiplying and increasing in number. By 20 days post infection, the spirochete resistant cells were seen uniformly throughout the flask.
Spirochetes also showed multiplication. The number of spirochetes increased. The spirochete resistant cells may provide some growth 2 0 factors for the multiplication of spirochetes.
After 12 days of culturing spirochetes in the cells, spirochetes were passaged in a new flask containing gut cells. In the first passage, the clumping of the cells was not seen until 4-5 days post infection. In this flask also, thespirochete ~tt~chmt-nt was seen only with small, round, clear cells. The large, round, 2 5 brown cells were not affected by spirochetes.
2. Amblyomma americanum These gut cells showed similar spirochete attachment. The only difference observed in this system was that clumping and attachment of spirochetes to cells was seen only after 4-5 days. The large, oval, brown cells were 3 0 not attacked by the spirochetes.
C. Anaplasma marginale This organism was obtained from peripheral blood collected from cattle suffering from anapl~cmosic or A. marginale-infected cattle in vacutainers containing heparin and which showed 27% par~citemi~3 as determined by blood smear 3 5 e~min~hon.
The buffy coat of A. mar~inale was removed by centrifugation and erythrocytes were washed 2x in L-lSB incomplete medium. The red blood cell ~VO 94/06463 21 ~ ~ 651 PCI/US93/08~
number was adjusted to 1.0 x 107 cells/mL in L-1~B complete meflium with all growth factors without antibiotics. Flasks containing approximately 5 mL of immortaliæd l~ermacentor andersoni and Amblvomma amencanum gut cells were inoculated with 1.0 x 106 celVmL infected erythrocytes (2 flasks for each cell type).
5 After inoculation, the cells were incubated at about 30C as described below.
Twenty-four hours post-inoculation of red blood cells (RBC~ into the culture, gut cells showed attachment of RBC onto the surface gut cells. This wasmore evident in Arnblyomma than the Derrnacentor cells (in both cell types theseattachments are seen). Forty-eight hours post-inoculation there was phagocytosis of 10 RBC by gut cells. The cell membrane of the gut cells became thick and numerous;
RBC were studded onto the surface of the gut cells. In addition, these gut cellsappeared dark brown.
Five days post-inoculation, the gut cells appeared highly granular, contained numerous minute uniform inclusion bodies, and many cells ruptured and 15 released these inclusion bodies into the surrounding medium. Culture samples were collected for tr~nsm;ssion electron microscopy for analysis of infected gut cells.
Changes were more evident in the Amblyomma cells.
Numerous modifications and variations of the present invention are included in the above-identified specification and are expected to be obvious to one 2 0 of skill in the art. Such modifications and alterations to the compositions and processes of the present invention are believed to be encompassed in the scope of the claims appended hereto.
Claims (36)
1. An irnmortalized tick cell line AGEC-1, ATCC Accession No. CRL
11083, its progeny and derivatives thereof.
11083, its progeny and derivatives thereof.
2. The immortalized cell line according to claim 1 infected with a selected pathogen.
3. The immortalized cell line according to claim 1 transfected with DNA
from a selected pathogen encoding a selected gene product under the control of regulatory sequences capable of expressing said gene product.
from a selected pathogen encoding a selected gene product under the control of regulatory sequences capable of expressing said gene product.
4. An immortalized tick cell line DGEC-1, ATCC Accession No. CRL
11084, its progeny and derivatives thereo
11084, its progeny and derivatives thereo
5. The immortalized cell line according to claim 4 infected with a selected pathogen.
6. The immortalized cell line according to claim 4 transfected with DNA
from a selected pathogen encoding a selected gene product under the control of regulatory sequences capable of expressing said gene product.
from a selected pathogen encoding a selected gene product under the control of regulatory sequences capable of expressing said gene product.
7. An immortalized bovine T cell line Bpbl-T1, ATCC Accession No.
CRL-11120, its progeny and derivatives thereof.
CRL-11120, its progeny and derivatives thereof.
8. The immortalized cell line according to claim 7 infected with a selected pathogen.
9. The irnmortalized cell line according to claim 8 transfected with DNA
from a selected pathogen encoding a selected gene product under the control of regulatory sequences capable of expressing said gene product.
from a selected pathogen encoding a selected gene product under the control of regulatory sequences capable of expressing said gene product.
10. An isolated pathogenic antigen produced by culturing an immortalized tick cell selected from the group consisting of AGEC-1, DGEC-1, progeny and derivatives thereof infected with a selected pathogen.
11. An isolated pathogenic antigen produced by culturing an immortalized bovine T cell line selected from the group consisting of Bpbl-T1, progeny and derivatives thereof infected with a selected pathogen.
12. An antigen produced by culturing an immortalized tick cell selected from the group consisting of AGEC-1, progeny and derivatives thereof transfectedwith DNA from a selected pathogen encoding a selected gene product under the control of regulatory sequences capable of expressing said gene product.
13. An antigen produced by culturing an immortalized tick cell selected from the group consisting of DGEC-1, progeny and derivatives thereof transfectedwith DNA from a selected pathogen encoding a selected gene product under the control of regulatory sequences capable of expressing said gene product.
14. An antigen produced by culturing an immortalized bovine T cell selected from the group consisting of Bpbl-T1, progeny and derivatives thereof, transfected with DNA from a selected pathogen encoding a selected gene product under the control of regulatory sequences capable of expressing the gene product.
15. A vaccine capable of protecting against infection with a selected pathogen comprising an immunogenic amount of at least one pathogenic antigen produced by culturing an immortalized tick cell selected from the group consisting of AGEC-1, DGEC-1, progeny and derivatives thereof infected with said selected pathogen.
16. A vaccine capable of protecting against infection with a selected pathogen comprising an immunogenic amount of a pathogenic antigen produced by culturing an immortalized bovine T cell selected from the group of cell lines consisting of Bpbl-T1, progeny and derivatives thereof infected with the selected pathogen.
17. The vaccine according to claim 16 wherein the pathogenic antigen is produced by transfecting said immortalized bovine T cell with DNA from the selected pathogen encoding the selected antigen under control of regulatory sequences capable of expressing the pathogenic antigen.
18. A vaccine capable of protecting against infection with a selected tick-borne pathogen and against infestation by a tick, wherein said vaccine composition comprises an immunogenic amount of an antigen obtained from an immortalized tickcell selected from the group consisting of AGEC-1, DGEC-1, progeny and derivatives thereof and an antigen from the selected tick-borne pathogen.
19. The vaccine according to claim 18 wherein the selected tick-borne pathogen is selected from the group consisting of Borrelia burgdorferi, Amblyomma americanum, Anaplasma marginale, Babesia bovis, Theileria parva, Cowdria ruminantium, Ehrlichia species, and arboviruses.
20. The vaccine according to claim 19 wherein said pathogenic antigen is produced by transfecting said immortalized tick cell with DNA from said selectedpathogen encoding a selected antigen under the control of regulatory sequences capable of expressing said antigen.
21. The vaccine according to claim 18 wherein said tick cell antigen is selected from the group consisting of a whole immortalized tick cell, a cellularfraction or subunit thereof, a protein and a macromolecule from said tick cell.
22. The vaccine according to claim 18 wherein the selected pathogen is produced by infecting the immortalized tick cell line with said pathogen.
23. A vaccine capable of protecting against tick infestation comprising an immunogenic amount of an antigen obtained from an immortalized tick cell selected from the group consisting of AGEC-1,DGEC-1, progeny and derivatives thereof.
24. The vaccine according to claim 21 wherein said tick cell antigen is selected from the group consisting of a whole immortalized tick cell, a cellularfraction or subunit thereof, a protein and a macromolecule from said tick cell.
25. A method of immunizing an animal against a disease caused by a selected tick-borne pathogen comprising internally administering to said animal a vaccine, wherein said vaccine composition comprises an immortalized tick cell antigen, said immortalized tick cell selected from the group consisting of AGEC-1, DGEC-1, progeny and derivatives thereof and an antigen from said selected pathogen.
26. The method according to claim 25 wherein said pathogen is Borrelia burgdorferi and said disease is Lyme disease.
27. A method of immnnizing an animal against tick infestation comprising the step of internally administering to said animal a vaccine comprising an immunogenic amount of an antigen obtained from an immortalized tick cell selected from the group consisting of AGEC-1,DGEC-1, progeny and derivatives thereof.
28. The vaccine according to claim 27 wherein said antigen is selected from the group consisting of (a) a whole immortalized tick cell, (b) a cellular fraction of said immortalized tick cell, (c) an immunogenic protein or macromolecule of saidimmortalized tick cell, and (d) a mixture of any one of (a), (b) and (c).
29. A method of immnnizing an animal against a disease caused by a selected pathogen comprising internally administering to the animal a vaccine composition comprising an immortalized bovine T cell selected from the group consisting of Bpbl-T1, progeny and derivatives thereof transfected with DNA fromthe selected pathogen encoding the selected antigen under control of regulatory sequences capable of expressing the antigen.
30. A method of immunizing an animal against a disease caused by a selected pathogen comprising internally administering to the animal a vaccine compositioncomprising an immortalized bovine T cell selected from the group consisting of Bpbl-T1, progeny and derivatives thereof infected with the selected pathogen.
31. A method of detecting the presence of a tick-borne pathogen in the body fluids of an animal comprising the step of incubating a body fluid sample taken from the animal in the presence of an antigen selected from the group consisting of (a) a whole immortalized tick cell selected from the group consisting of AGEC-1, DGEC-1, progeny and derivatives thereof, (b) a cellular fraction of said immortalized tick cell, (c) an immunogenic protein or fragment of said immortalized tick cell, and (d) a mixture of any one of (a), (b) and (c).
32. An antibody specific for a receptor on an immortalized tick cell selected from the group consisting of AGEC-1, DGEC-1, progeny and derivatives thereof.
33. An antibody specific for a receptor on an immortalized bovine T cell selected from the group consisting of Bpbl-T1, progeny and derivatives thereof.
34. A therapeutic composition useful for treating tick infestations comprising an antigen selected from the group consisting of (a) a whole immortalized tick cell selected from the group consisting of AGEC-1, DGEC-1, progeny and derivatives thereof, (b) a cellular fraction of said immortalized tick cell, (c) an immunogenic protein or fragment of said immortalized tick cell, and (d) a mixture of any one of (a), (b) and (c).
35. A diagnostic reagent comprising an antigen selected from the group consisting of (a) a whole immortalized tick cell selected from the group consisting of AGEC-1, DGEC-1, progeny and derivatives thereof, (b) a cellular fraction of saidimmortalized tick cell, (c) an immunogenic protein or fragment of said immortalized tick cell, and (d) a mixture of any one of (a), (b) and (c).
36. A diagnostic reagent comprising an antigen selected from the group consisting of (a) a whole immortalized bovine cell selected from the group consisting of Bpbl-T1, progeny and derivatives thereof, (b) a cellular fraction of said immortalized bovine cell, (c) an immunogenic protein or fragment of said immortalized bovine cell, and (d) a mixture of any one of (a), (b) and (c).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94487392A | 1992-09-14 | 1992-09-14 | |
US07/944,873 | 1992-09-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2144651A1 true CA2144651A1 (en) | 1994-03-31 |
Family
ID=25482205
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002144651A Abandoned CA2144651A1 (en) | 1992-09-14 | 1993-09-14 | Immortalized cells and uses therefor |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0749319A1 (en) |
JP (1) | JPH08502646A (en) |
AU (2) | AU5103293A (en) |
CA (1) | CA2144651A1 (en) |
WO (1) | WO1994006463A1 (en) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5989866A (en) | 1996-10-16 | 1999-11-23 | Zymogenetics, Inc. | FGF homologs |
US6017757A (en) * | 1997-02-20 | 2000-01-25 | Mississippi State University | Isolated viable nematode intestinal cells |
CZ20011026A3 (en) | 1998-09-23 | 2001-08-15 | Zymogenetics, Inc. | Isolated polynucleotide, expression vector, cultivated cell, DNA construct, production process of protein, isolated polypeptide, production process of antibody, antibody per se and detection method |
CA2354325C (en) | 1998-12-07 | 2011-08-16 | Zymogenetics, Inc. | Growth factor homolog zvegf3 |
US7833529B1 (en) | 1999-01-07 | 2010-11-16 | Zymogenetics, Inc. | Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor |
AU780805B2 (en) | 1999-01-07 | 2005-04-21 | Ares Trading S.A. | Soluble receptor BR43x2 and methods of using |
CA2366921C (en) | 1999-03-09 | 2013-12-17 | Zymogenetics, Inc. | Novel cytokine zalpha11 ligand |
JP2003524415A (en) | 1999-12-23 | 2003-08-19 | ザイモジェネティクス,インコーポレイティド | Cytokine ZCYTO18 |
DK1325115T3 (en) | 2000-06-26 | 2016-11-21 | Zymogenetics Inc | CYTOKINRECEPTOR ZCYTOR17 |
WO2003040313A2 (en) | 2001-11-05 | 2003-05-15 | Zymogenetics, Inc | Il-21 antagonists |
EP1961811B1 (en) | 2002-01-18 | 2010-08-25 | ZymoGenetics, Inc. | Cytokine ligand for the treatment of asthma and airway hyper-responsiveness |
EP2338910B1 (en) | 2002-01-18 | 2015-07-08 | ZymoGenetics, Inc. | Cytokine receptor Zcytor17 multimers |
JP4409962B2 (en) | 2002-04-19 | 2010-02-03 | ザイモジェネティクス,インコーポレイティド | Cytokine receptor |
CN1910200A (en) | 2003-08-07 | 2007-02-07 | 津莫吉尼蒂克斯公司 | Homogeneous preparations of IL-28 and IL-29 |
WO2005087810A2 (en) | 2004-03-08 | 2005-09-22 | Zymogenetics, Inc. | Dimeric fusion proteins and materials and methods for producing them |
EP1793845A2 (en) | 2004-07-29 | 2007-06-13 | ZymoGenetics, Inc. | Use of il-28 and il-29 to treat cancer |
AU2006278227B2 (en) | 2005-08-09 | 2011-10-20 | Ares Trading S.A. | Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules |
CA2618765A1 (en) | 2005-08-09 | 2007-02-15 | Zymogenetics, Inc. | Methods for treating b-cell malignancies using taci-ig fusion molecule |
UA98462C2 (en) | 2006-05-15 | 2012-05-25 | Арес Трейдинг С.А. | Methods for treating autoimmune diseases using a taci-ig fusion molecule |
AU2007254824A1 (en) | 2006-06-02 | 2007-12-13 | Wyeth | Use of proteins and peptides of the TGF-beta superfamily for purification and therapeutic methods |
US7754689B2 (en) | 2006-06-02 | 2010-07-13 | Wyeth Llc | Finger-1 peptide analogs of the TGF-β superfamily |
WO2008057396A2 (en) * | 2006-11-03 | 2008-05-15 | Schering-Plough Ltd. | Canine lyme disease vaccine |
WO2008157263A2 (en) | 2007-06-15 | 2008-12-24 | Arkansas State University | Methods of delivery of molecules to cells using a ricin subunit and compositions relating to same |
SI2274008T1 (en) | 2008-03-27 | 2014-08-29 | Zymogenetics, Inc. | Compositions and methods for inhibiting pdgfrbeta and vegf-a |
US8658766B2 (en) | 2008-06-27 | 2014-02-25 | Zymogenetics, Inc. | Soluble hybrid Fcγ receptors and related methods |
MX2012013899A (en) | 2010-06-09 | 2013-03-20 | Zymogenetics Inc | Dimeric vstm3 fusion proteins and related compositions and methods. |
DK2809795T3 (en) | 2012-02-01 | 2019-12-16 | Sgi Dna Inc | MATERIALS AND PROCEDURES FOR SYNTHESIS OF ERROR-MINIMIZED NUCLEIC ACID MOLECULES |
CA2997263C (en) | 2015-09-08 | 2022-10-04 | Theripion, Inc. | Apoa-1 fusion polypeptides and related compositions and methods |
WO2018136163A2 (en) | 2016-12-09 | 2018-07-26 | Theripion, Inc. | Tandem apoa-1 fusion polypeptides |
BR112020001180A2 (en) | 2017-07-20 | 2020-09-08 | Aptevo Research And Development Llc | antigen-binding proteins that bind to 5t4 and 4-1bb and related compositions and methods |
AU2018391831B2 (en) | 2017-12-20 | 2022-08-04 | Harbour Biomed (Shanghai) Co., Ltd | Antibodies binding CTLA-4 and uses thereof |
EP3732190A1 (en) | 2017-12-27 | 2020-11-04 | Imunami Laboratories Pte. Ltd. | Recombinant polypeptides and methods of use thereof |
US10150801B1 (en) | 2017-12-27 | 2018-12-11 | Imunami Laboratories Pte. Ltd. | Recombinant polypeptides and methods of use thereof |
US10675332B1 (en) | 2019-08-26 | 2020-06-09 | Imunami Laboratories Pte. Ltd. | Recombinant polypeptides and methods of use thereof |
EP4021512A1 (en) | 2019-08-26 | 2022-07-06 | Imunami Laboratories Pte. Ltd. | Recombinant polypeptides and methods of use thereof |
AU2020454690A1 (en) | 2020-06-22 | 2023-02-02 | Imunami Laboratories Pte. Ltd. | Recombinant polypeptides and combinations for use in the treatment of cancer |
WO2022178090A2 (en) | 2021-02-19 | 2022-08-25 | Theripion, Inc. | Dnase fusion polypeptides and related compositions and methods |
WO2024148328A2 (en) | 2023-01-06 | 2024-07-11 | Aptevo Research And Development Llc | Bispecific pd-l1 and cd40 binding molecules and uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4447537A (en) * | 1981-01-22 | 1984-05-08 | The United States Of Americas As Represented By The Department Of Health And Human Services | Tick cell lines |
IL84574A (en) * | 1986-11-27 | 1994-10-07 | Biotech Australia Pty Ltd | Antigen from cattle tick, parts, homologues and epitopes thereof having similar immunological activity, process for preparing them, polynucleotide encoding them, vaccines containing them, antibodies derived therefrom and method for protecting animals against tick infestation |
US5186933A (en) * | 1986-12-30 | 1993-02-16 | Baylor College Of Medicine | Synthesis and immunogenicity of rotavirus genes using a baculovirus expression system |
-
1993
- 1993-09-14 JP JP6508223A patent/JPH08502646A/en active Pending
- 1993-09-14 WO PCT/US1993/008606 patent/WO1994006463A1/en not_active Application Discontinuation
- 1993-09-14 EP EP93920511A patent/EP0749319A1/en not_active Withdrawn
- 1993-09-14 CA CA002144651A patent/CA2144651A1/en not_active Abandoned
- 1993-09-14 AU AU51032/93A patent/AU5103293A/en not_active Abandoned
-
1997
- 1997-12-11 AU AU48314/97A patent/AU4831497A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JPH08502646A (en) | 1996-03-26 |
EP0749319A4 (en) | 1996-09-16 |
AU4831497A (en) | 1998-03-26 |
EP0749319A1 (en) | 1996-12-27 |
AU5103293A (en) | 1994-04-12 |
WO1994006463A1 (en) | 1994-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2144651A1 (en) | Immortalized cells and uses therefor | |
Williams et al. | Immunological and biological characterization of Coxiella burnetii, phases I and II, separated from host components | |
Pinto et al. | Immune response to virus-infection-associated (VIA) antigen in cattle repeatedly vaccinated with foot-and-mouth disease virus inactivated by formalin or acetylethyleneimine | |
Gottstein et al. | Antigenic variation in Giardia lamblia: cellular and humoral immune response in a mouse model | |
EP0018579B1 (en) | Babesiosis antigen, vaccine and diagnostic reagent comprising it | |
Mellor et al. | Experimental transmission of African swine fever virus by Ornithodoros savignyi (Audouin) | |
Lewis, BD*, Penzhorn, BL** & Lï¿ ½pez Rebollar | Immune responses to South African Babesia canis and the development of a preliminary vaccine | |
US8034571B1 (en) | Microbial polynucleotides expressed during infection of a host | |
Finlay et al. | The use of the complement fixation test for rapid typing of infectious pancreatic necrosis virus | |
Uchida et al. | Immunofluorescence test with Rickettsia montana for serologic diagnosis of rickettsial infection of the spotted fever group in Shikoku, Japan | |
US7033748B2 (en) | Identification of microbial polynucleotides expressed during infection of a host | |
US4759927A (en) | Vaccine against Potomac horse fever and method of preparation therefore | |
KR20100070334A (en) | Methods of culturing bacterial species of the anaplasmataceae family | |
US11623945B2 (en) | Immunostimulating compositions and uses therefore | |
RU2341288C1 (en) | MEDICINE FORMING CELLULAR IMMUNITY FOR MYCOBACTERIUM TUBERCULOSIS H37 Rv, METHOD OF PRODUCTION THEREOF (VERSIONS), RECOMBINANT STRAIN AND TUBERCULOSIS DIAGNOSTIC AGENT | |
Wainberg et al. | Immune selection of tumor cell variants in chickens bearing tumors induced by avian sarcoma virus | |
RU2798283C1 (en) | Chlamydia vnitibp-21 chlamydia abortus strain for the production of immunobiological medicinal products | |
RU2802251C1 (en) | Vaccine composition for the prevention of enzootic abortion in sheep | |
JPH02295934A (en) | Dog coronavirus vaccine | |
WO1983000017A1 (en) | Anaplasma antigen | |
RU2026081C1 (en) | Brucellosis vaccine for farm animals | |
CN118480515A (en) | Porcine reproductive and respiratory syndrome virus NADC30 virus strain and application thereof | |
JPH0118885B2 (en) | ||
RU2026343C1 (en) | Vaccine against brucellosis in farming animals | |
RU2113857C1 (en) | Vaccine against brucellosis in cattle |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |